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Introduction: Bipolar Disorder (BPD) is a severe, neuropsychiatric disorder which 
affects approximately 1% of the population. Due to the high heritability of BPD, genetic 
variations amongst affected individuals have been investigated. Recently, researchers 
have developed a method termed Convergent Functional Genomics (CFG) which aims to 
identify a prioritized candidate gene list, based on the results of previous studies, 
underlying the pathology of BPD and other psychiatric illnesses. In addition, neuro-
imaging studies have revealed that BPD is associated with structural changes in the brain 
and that certain brain regional volumes are heritable. 
 
Aims and Objectives: The aims were to determine whether variants, within ten selected 
candidate genes, have an association with BPD and whether any relationship exists 
between these variants and brain imaging volumes in subjects with BPD. The objectives 
were to i) select a list of BPD candidate genes, ii) identify a cohort of individuals from the 
BPD registry, iii) genotype the candidate genes using a polymerase chain reaction (PCR) 
based technology, iv) analyse the genotyping data with the appropriate statistical 
methods, and v) obtain brain imaging data and perform the appropriate statistical 
analysis  
 
Materials and Methods: Candidate genes were selected based on the most significant 
findings of previous publications. Multiplex SNaPshotTM PCR was used to genotype 224 













of Mixed Ancestry and Caucasians, affected with BPD Type I. Magnetic resonance imaging 
(MRI) data was collected for a subset of the case group (n=22). 
 
Results: Preliminary results suggest  associations between SNPs in the candidate genes, 
ankyrin3 (ANK3), ataxin-2 binding protein1 (A2BP1) and myelin basic protein (MBP), with 
BPD. No significant associations were found between genotypes and brain imaging data.  
 
Conclusions: These results suggest that BPD may have a common aetiology with 
neurodegenerative disorders. Polymorphisms within ANK3, A2BP1 and MBP should be 
further investigated to determine the specific effects of these variants on the expression 
















Chapter 1: Introduction 
 
Bipolar Disorder (BPD) is a severe psychiatric illness which is characterized by extremes 
in mood and affects approximately 1% of the population. Much research has been 
undertaken to determine the underlying causes of this highly heterogeneous disorder. 
However, due to its high heritability, genetic factors have been thought to be a major 
contributor to the underlying aetiology. Recently, researchers have developed a 
Convergent Functional Genomics (CFG) approach which aims to derive a prioritized 
candidate gene list, based on the results of a wide range of previous studies, including 
brain imaging and animal models. The 113 CFG prioritized genes that have been 
identified comprise those involved in a wide range of central nervous system (CNS) 
function including neuronal maintenance, circadian rhythm regulation and 
transcriptional regulation [Le-Niculescu et al., 2008]. In addition, several other genes 
have been implicated through hypothesis-free genome-wide association studies (GWAS) 
[Stratton, 2007; Baum et al., 2008; Ferreira et al., 2008; Sklar et al., 2008; Zhang et al., 
2008; Hattori et al., 2009; Scott et al., 2009; Smith et al., 2009]. Many of these genes 
overlap with those identified by the CFG approach and are ideal candidates to 
interrogate in studies investigating the aetiology of BPD. 
 
1.1 Features and Characteristics of Bipolar Disorder 
BPD is a severe, debilitating mental disorder affecting approximately 1% of the 
population [Merikangas et al., 2007]. This disorder is characterized by mood episodes 
ranging from an elevated mood to severe depression [Ogden et al., 2004]; onset usually 













[Miller, 2006]. The affected individual may experience a decline in quality of life, 
productivity, and longevity [Thase and Denko, 2008] and psychotic features such as 
delusions and hallucinations may also be a feature [American Psychiatric Association. 
Task Force on DSM-IV, 1994]. Individuals with BPD have greater difficulty in sustaining 
interpersonal relationships and have trouble maintaining employment compared to 
those without mood disorders: a total of 54% of affected individuals were dismissed 
from their jobs compared to 29% of a matched unaffected group [Calabrese et al., 2003]. 
The same study showed that persons suffering with the disorder have difficulty abiding 
by the law; and have a significantly higher chance of being arrested for crimes. Violent 
behaviour is often observed during manic episodes [American Psychiatric Association. 
Task Force on DSM-IV, 1994]. In 1991, the total economic burden of BPD in the USA was 
estimated at US $45 billion. This cost is attributed to medication, hospitalisation, 
misdiagnosis, and the estimated financial burden due to productivity loss [Hirschfeld and 
Vornik, 2005]. Between 10% and 20% of patients successfully commit suicide [Müller-
Oerlinghausen et al., 2002; Bauer and Pfennig, 2005]. Currently, the diagnosis of BPD is 
based exclusively on clinical symptoms as the molecular pathology has yet to be 
discovered [Craddock and Sklar, 2009]. 
 
Based on different symptomatic criteria, there are several types of BPD distinguishable 
in the population: i) BPD type I (BPDI), ii) BPD type II (BPDII), iii) Cyclothymia, and iv) 
“BPD not otherwise specified” (BPDNOS) [American Psychiatric Association. Task Force 
on DSM-IV, 1994]. For the purposes of this study, a more detailed description of BPDI, 













1.1.1 DSM-IV criteria for BPDI 
According to DSM-IV (Diagnostic and Statistical Manual of Mental Disorders-IV) criteria 
[American Psychiatric Association. Task Force on DSM-IV, 1994], BPDI is a recurrent 
mood disorder, characterized by the presence of one or more manic or mixed episodes 
(see Table 1 for diagnostic criteria of each mood episode). The occurrence of one or 
more major depressive episodes may also be a feature. The mania associated with BPDI 
should not be due to Substance-Induced Mood Disorder or Schizoaffective Disorder. 
During severe manic episodes violent or abusive behavior may be experienced. On 
average, untreated BPDI patients experience four episodes each decade. There are no 
differences in BPDI prevalence across gender and ethnicity. However, it has been noted 
that males are more likely to experience a manic episode before a depressive episode 
and vice-versa for females. Most individuals return to an improved or functional state 
between episodes [American Psychiatric Association. Task Force on DSM-IV, 1994]. 
1.2 Kraeplinian Dichotomy: BPD and Schizophrenia 
Less than a hundred years ago, Emil Kraepelin classified Schizophrenia (SCZ) and BPD as 
being two separate disease entities, which he termed dementia praecox and manic-
depression, respectively. In other words, each disorder has a different underlying cause 
[Craddock and Owen, 2005; Greene, 2007]. However, these two disease entities share 
common clinical symptoms [Maier et al., 2005] and there exists an intermediate 
phenotype, termed Schizoaffective Disorder [Lichtenstein et al., 2009]. Schizoaffective 
Disorder is characterized by features of both SCZ and BPD [Craddock et al., 2009]. Family 
history research has shown the occurrence of SCZ and BPD in the same family 
[Wildenauer et al., 1999]. Relatives of BPD patients have an increased risk for SCZ, 













This suggests a genetic/biological overlap between the two groups of disorders [Maier et 
al., 2005]. There is a greater amount of genetic information available pertaining to the 
aetiology of SCZ than there is for BPD [McGuffin et al., 2003].  
Table 1: Diagnostic criteria of mood episodes characteristic of BPD  
Episode DSM-IV Criteria 
Major Depressive 
Episode (MDE) 
a) Five or more of the following symptoms 
 Depressed or irritable (children and adolescents) mood 
 Decreased interest or pleasure in almost all activities 
 Significant changes in body weight 
 Insomnia or hypersomnia  
 Psychomotor agitation 
 Fatigue and decrease in energy 
 Feelings of worthlessness and excessive guilt 
 Diminished concentration and increased indecisiveness 
 Increased thoughts of death and suicidal ideation 
b) Symptoms do not meet criteria for mixed episode 
c) Symptoms cause functional impairment 
d) Symptoms not a result of physiological effect of 
substance 
e) Symptoms not as a result of bereavement and are 
present for longer than two months   
Manic Episode 
a) Period of abnormally elevated or irritable mood 
lasting at least one week 
b) Three or more of the following symptoms are 
present to a significant degree 
 Inflated self-esteem or grandiosity 
 Decreased need for sleep 
 Talkative 
 Racing thoughts 
 Easily distractible 
 Increased goal-directed activity or psychomotor 
agitation 
 Excessive participation in pleasurable activities with 
potential for painful consequences 
c) Symptoms do not meet criteria for mixed episode 
d) Symptoms cause functional impairment 















Table 1: Diagnostic criteria of mood episodes characteristic of BPD continued 
Mixed Episode 
a) Criteria met for both Major Depressive Episode and 
Manic Episode nearly every day during a one week 
period 
b) Symptoms cause functional impairment 




a) Period of abnormally elevated or irritable mood 
lasting at least four days 
b) Three or more of the following symptoms are 
present to a significant degree 
 Inflated self-esteem or grandiosity 
 Decreased need for sleep 
 Talkative 
 Racing thoughts 
 Easily distractible 
 Increased goal-directed activity or psychomotor 
agitation 
 Excessive participation in pleasurable activities with 
potential for painful consequences 
c) Change in functioning  
d) Disturbance in mood observable by others 
e) Episode not severe enough to caused marked 
functional impairment 
f) Symptoms not a result of physiological effect of 
substance 
 
[American Psychiatric Association (DSM-IV), 2005] 
 
1.3 Techniques Used to Determine the Aetiology of BPD 
1.3.1 Mouse Models  
Mouse models have proven to be a reliable resource for geneticists. With the completion 
of the mouse genome sequence and the relative abundance of different mouse strains, 
the phenotypic effects of certain mutations are relatively easily observable [Seong et al., 













manipulation [Le-Niculescu et al., 2008]. In general, an animal model needs to meet the 
following three criteria in order for it to be considered effective:  
 
(a) Face Validity- the model should have similar behavioural patterns as human disease.  
(b) Construct Validity- the model should have the same or similar underlying 
pathological characteristics as the human disease.  
(c) Predictive Validity- Symptoms of the animal model that are characteristic of human 
disease should improve with administration of medication [Jornada et al., 2009].  
 
An animal model of BPD would help in the understanding of the aetiology as well as 
provide a means to test treatment options. However, due to the cyclical nature of BPD, 
the innovation of an animal model, which meets all three criteria, has proven to be 
elusive. There are models which mimic certain characteristics of the disorder, such as 
depression and mania, but none are able to provide a mechanism by which mood states 
are alternated [Machado-Vieira et al., 2004]. Each of the existing BPD models can be 
categorized as either pharmacological, nutritional, environmental, or genetic [Kato et al., 
2007]. An example of each category is discussed below:  
 
 
i) Pharmacological Model: Ouabain- It has been shown that sodium-
potassium-ATPase function is significantly reduced in individuals suffering 
from psychiatric disorders and that affected individuals appear to have 
increased intracellular levels of sodium and calcium [el-Mallakh et al., 1995], 













of sodium-potassium-ATPase and has been shown to induce a manic-like state 




ii) Nutritional Model: Homocysteine- Serum levels of homocysteine, a 
neurotoxin, has been found to be elevated in BPD patients. This is due to the 
effects of diet, inadequate vitamin B consumption, a decrease in physical 
exercise and an increase in smoking. In a mouse model, mild cognitive 
impairments were observed after chronic exposure to homocysteine [Levine 
et al., 2005].  
 
 
iii) Environmental Model: Learned Helplessness (LH)- This mouse model is 
used to represent depression. This model, which is developed by treating the 
animal with electroshocks, displays symptoms of human depression and is 
unable to cope under difficult situations. The symptoms of this model are 
alleviated with the administration of antidepressants [Nakatani et al., 2004]. 
 
 
iv) Genetic Model: Glucocorticoid Overexpression- Glucocorticoid receptors 
have several functions including modulation of stress response and cognition. 
Overexpression of glucorcorticoid receptors in the forebrain have shown an 














1.3.2 Human Gene Expression Data 
Due to the nature of BPD, the brain would be the preferable tissue for gene expression 
studies. However, this may only be obtained from postmortem tissue which may present 
with a few disadvantages; for example, gene expression may be significantly altered due 
to death, tissue preservation methods [Matigian et al., 2007] or medication [Nakatani et 
al., 2006].  
 
Nevertheless, Nakatani et al. [2006] performed a genome-wide expression study on 
seven postmortem BPD brains and seven control brains. They found 108 genes were 
differentially expressed in BPD brains and that these genes only had a minimal fold 
change. This is in keeping with the hypothesis that psychiatric illnesses are a 
manifestation of subtle changes in gene expression. Pathway analysis indicated that most 
of the genes could be classified as either forming part of the processes of cellular growth 
and proliferation, nervous system development, or cell death. In another expression 
study, also involving postmortem brains, pathways that were over-represented included 
the G-protein coupled receptor signaling pathway, stimulus response pathways, 
intracellular transport, and the ubiquitin cycle [Ryan et al., 2006]. Table 2 lists some of 
the expression studies that have been performed and the major pathways that have been 
implicated in each. There appears to be no consensus of results amongst these 
expression studies. This could be due to different tissue “quality” in each of the studies 
which in turn has an effect on tissue pH levels. For example, energy metabolism and 















Table 2: Genes and pathways implicated in human expression studies 














Iwamoto et al. [2004]  






Iwamoto et al. [2005] Mitochondria-related  brain 
Prefrontal 
Cortex 
Nakatani et al. [2006] 
Cellular growth, proliferation 






Ryan et al. [2006] 
G-protein coupled receptor signaling 













1.3.3 Human Blood Evidence 
Currently, there are no available blood tests that can be used to determine the presence 
of a mood disorder in a patient. Diagnosis is strictly limited to clinical symptoms and 
patient self-report [Craddock and Sklar, 2009]. This presents with certain disadvantages 
to psychiatrists in obtaining an accurate diagnosis which is necessary for effective 
treatment and management. Therefore, discovery of appropriate peripheral tissue 













these types of studies have proven to be inconclusive and a definitive or other blood 
biomarker has yet to be discovered. 
 
1.3.4 Genetics and Family Studies 
Studies have shown that BPD has heritability estimates ranging from 59% to 85% 
[Lichtenstein et al., 2009; McGuffin et al., 2003]. First degree relatives and half-siblings of 
affected individuals are at a significantly increased risk (5-10%) of developing the 
disorder [Müller-Oerlinghausen et al., 2002; Lichtenstein et al., 2009]. Adoption studies 
have revealed that the biological relatives of a proband have a 31% higher risk of 
developing BPD than the relatives of control individuals. In a BPD twin study, it was 
shown that monozygotic and dizygotic twins have a 67% and 19% concordance, 
respectively [McGuffin et al., 2003]. Therefore, genetics is thought to hold a key to the 
understanding of BPD. However, efforts at elucidating the genetic cause of this disorder 
have been hampered by genetic heterogeneity, environmental factors and phenotypic 
variability that characterise BPD [Le-Niculescu et al., 2008]. As a result, researchers have 
adopted different approaches to determine the factors underlying the pathophysiology 
of BPD. One of these approaches involves the examination of intermediate phenotypes 
which are associated with the disorder under investigation but are easier to investigate 
genetically [Gottesman and Gould, 2003]. It is thought that discovering the genetic 
components of the more homogenous endophenotypes will aid in the understanding of 
genetically complex disorders like BPD. A particular trait needs to meet the following 














 Is associated with a disorder in the population 
 
 Is heritable 
 
 Is evident in individuals whether the disorder is active or not 
 
 Co-occurs with disease within families 
 
 Manifests in non-affected family members of affected individuals at a 
higher frequency than in the general population  
 
1.3.4.1 Linkage and Association Studies 
The candidate approach investigates genes which have been reported to be linked to 
disease in previous research, or focuses on loci based on their purported role in the 
biology of the disorder. Linkage analysis involves the genotyping of genetic markers 
which are significantly associated with a disease phenotype. These approaches are more 
cost-effective than GWAS but require a hypothesis regarding the relationship of the gene 
to disease [Hirschhorn and Daly, 2005]. Regions on chromosomes 6, 7, 8, 10, 11, 12, 13, 
15, 16, 17, and 22 have previously been reported to be linked to the BPDI phenotype 
[Ogden et al., 2004; Neves-Pereira et al., 2002; Sklar et al., 2002; Hattori et al., 2003; 
Chen et al., 2005; Schumacher et al., 2004; Fallin et al., 2005; Martucci et al., 2006; 













1.3.4.2 Genome-Wide Association Studies 
Over the last several years, researchers interested in mapping the genetic basis of 
several complex disorders have invested their resources in GWAS which do not require 
an a priori hypothesis. GWAS utilize high-throughput genotyping methods, on very large 
cohorts of subjects/patients and controls, to determine whether genetic variants, such as 
single nucleotide polymorphisms (SNPs) spread across the genome, have an association 
with disease status compared to equally large numbers of controls [Hirschhorn and Daly, 
2005]. To date, eight GWAS have been performed on BPD cohorts; these are summarized 
in Table 3.  
 
In 2007, The Wellcome Trust Case- Control Consortium (WTCCC) carried out a GWAS for 
seven common diseases, one of which was BPD [Stratton, 2007]. Their strongest signal of 
association for BPD was in the region of chromosome 16p12, which includes genes such 
as PALB2 (partner and localiser of BRCA2), NDUFAB1 (NADH dehydrogenase (ubiquinone) 
1, alpha/beta subcomplex, 1), and DCTN5 (dynactin 5) [Stratton, 2007]. The subsequent 
GWAS for BPD implicated genes such as DGKH (diacylglycerol kinase), ANK3 (ankyrin 3), 
and CACNA1C (Calcium Channel, Voltage-Dependent, L type, Alpha 1C  Subunit) [Baum et 
al., 2008; Ferreira et al., 2008]. However, the results from these studies have proven 




























BPD Caucasian SNPs 16p12 Affymetrix GeneChip 500K 





BPDI Caucasian SNPs DGKH (13q14.11) Illumina HumanHap550 




BPDI Caucasian SNPs 
MYO5B (18q21) 
TSPAN8 (12q14.1) 
Affymetrix GeneChip 500K 
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BPDI, SABP Caucasian SNPs and CNVs - Affymetrix SNP 6.0 
Hattori et al. 
[2009] 























PCDH15 (10q21.1), MYT1L 
(2p25.3), CSMD1(8p23.2), 















BPDI Caucasian SNPs 
1p31.1, 3p21 (ITIH1, GNL3 
NEK4, ITIH3), 5q15(MCTP1), 
Illumina HumanHap550 





















Affymetrix SNP 6.0 












1.3.5 Brain Imaging 
Research within psychiatry has investigated the links between disease states, genotypes, 
psychological processes and brain structure and function. This effort has been facilitated 
by the development of recent neuro-imaging techniques [Dager et al., 2008]. Over the 
past 30 years, neuro-imaging studies have revealed that BPD is associated with 
structural changes in the brain [Vita et al., 2009]. However, different regions of the brain 
have been implicated and replication studies have proven to be inconclusive. Also, the 
causal reason, age of onset, and course of these brain abnormalities in affected 
individuals are still largely unknown [Vita et al., 2009]. Magnetic resonance imaging 
(structural–voxel based morphometry (VBM)) is a commonly used imaging technique 
that is discussed below in greater detail.  
 
1.3.5.1 Magnetic Resonance Imaging (MRI) 
This technique is able to provide a high resolution, three-dimensional view of soft 
tissues. The main advantage of this technique is its relative safety as it is non-invasive 
and does not involve any ionizing radiation [Leondes, 2005]. The MRI image is obtained 
by the use of a tomograph. The main constituent of this instrument is a large cylindrical 
coil which functions as a magnet. There are additional coils which form part of an electric 
circuit, whereby the electrical current within the magnet is able to produce a steady 
magnetic field. The subject is placed inside the cylindrical coil and exposed to the 













MRI relies on nuclear magnetic resonance (NMR), whereby protons and neutrons that 
constitute the nucleus of a molecule, have what is known as an angular momentum or 
spin [Leondes, 2005]. MRI involves the interaction between the nuclear spin of a proton 
within the nucleus of a hydrogen atom and the applied magnetic field. The human body 
consists mainly of lipids (~33%) and water (~70%) [Sheng and Huggins, 1979] hence, 
an abundance of hydrogen atoms in the brain [Leondes, 2005]. These “protons” once 
placed in a magnetic field, absorb radio waves (electromagnetic energy) at a certain 
frequency, and align themselves to the magnetic field by releasing the absorbed energy 
[Sajjad and Alam, 2007].  
 
A meta-analysis of MRI studies for first episode BPD patients indicated that intracranial 
as well as white matter volumes were significantly lower in affected individuals 
compared to controls [Vita et al., 2009]. The authors propose that the apparent 
deficiency in white matter may indicate irregular neural development of the brain. 
Reduction in grey matter volumes has also often been found to be associated with BPD. 
Sassi et al. [2002] found that lithium treatment increased grey matter volumes compared 
to untreated patients. However, changes in grey matter volume could not be replicated in 
other studies [Vita et al., 2009; McDonald et al., 2005; Scherk et al., 2008]. These 
discrepancies in results could be due to the effects of medication and small sample sizes 
[van der Schot et al., 2009], suggesting a need for additional studies. Several studies have 
examined the relationship between hippocampal volumes and BPD [Blumberg et al., 
2003; Rimol et al., 2010]. Findings from these studies suggest that individuals affected 












matter volumes, treatment with lithium appeared to increase the hippocampal volumes 
of affected individuals compared to unmedicated individuals [Yucel et al., 2008]. 
 
1.3.5.2 Imaging Genetics  
Certain brain volumes have been shown to be heritable [Goldman et al., 2008]. For 
example, twin studies have shown that frontal lobe structures and the hippocampus have 
heritabilities of 90-95% and 40-69%, respectively [Peper et al., 2007]. These findings 
indicate that genes may underlie the variation in brain structures seen across 
individuals.  
 
van der Schot et al. [2009] examined the effects of genes and the environment on brain 
volumes in twin pairs concordant and discordant for BPD. They concluded that a 
decrease in white matter is associated with a genetic risk for developing BPD. This 
finding was also found in a previous twin study [Kieseppä et al., 2003]. Similarly, another 
twin study found that hippocampal volumes were smaller in the affected twin when 
compared to the unaffected co-twin [Noga et al., 2001]. It is thought that genes 
underlying BPD may be the cause for the observed decreases in white matter and 
hippocampal volumes. However, the biological mechanisms underlying these 
associations are still unknown. 
 
Brain structural volumes and function have been investigated as endophenotypes of 
psychiatric illnesses [McDonald et al., 2004; Cannon and Keller, 2006; Glahn et al., 2007]. 












field which has received some attention of late is that of imaging genetics. Imaging 
genetics is a type of genetic association study in which genotypes are correlated with 
brain structure or function. This type of study is favoured as it gives a direct indication of 
the effect of underlying genetics on brain structure and function [de Geus et al., 2008] 
which may aid in the understanding of the genetics underlying complex psychiatric 
illnesses.  
 
1.4 Convergent Functional Genomics 
Due to the high heritability and familial pattern of inheritance of BPD, researchers have 
commonly focused on the genetics of this disorder. Many of these studies, as discussed 
previously, have focused on single gene approaches or expression studies which have, in 
turn, generated results implicating numerous genes. However, most of these findings 
could not be replicated particularly in those studies involving differing ethnic groups. 
With this abundance of data available it has become difficult to determine which finding 
would most likely be significant for follow-up studies. Therefore, researchers have 
focused their attention on a more comprehensive integrated approach to determine the 
genetic components of this and other psychiatric disorders. Le Niculescu et al. [2008] 
devised a gene prioritization method which they have termed CFG. CFG integrates data 
generated from GWAS together with results obtained from independent genomic 
investigations such as association or linkage studies, animal models and gene expression 
data. This approach aims to provide a means of prioritizing candidates for future 
hypothesis-driven studies [Le-Niculescu et al., 2008]. Using this approach, Le-Niculescu 












1.5 Candidate Genes 
All of the candidate genes and respective SNPs that have been investigated in the current 
study are described below and summarised in Table 4. 
 
1.5.1 KLF12 
This gene has not been functionally implicated in any psychiatric disorder but has been 
one of the genes that obtained the highest CFG score out of a total of 113 genes [Le-
Niculescu et al., 2008]. KLF12 is a member of a family of 16 kruppel-like factors (KLFs) 
that are DNA binding transcriptional regulators. Through their role as gene regulators, 
KLFs are involved in numerous cellular processes such as proliferation, apoptosis and 
development [Zhang et al., 2005]. KLF12 is located on chromosome 13q22.1 and is 
specifically involved in the repression of the AP-2 alpha gene [Roth et al., 2000]. AP-2 
genes have been implicated in the pathophysiology of cancers as they play a role in 
tumour progression [Roth et al., 2000]. With this, KLF12 is also thought to play a role in 
the development of cancers. A recent study implicated KLF12 in gastric cancers, and 
proposed this gene as a target for therapeutic intervention [Nakamura et al., 2009]. 
Baum et al. [2008] found that an intronic SNP (rs9600160) within KLF12 was associated 
with BPD (p< 0.05).  
 
1.5.2 ARNTL 
ARNTL (also known as BMAL1), is located on chromosome 11p15.2 and encodes the aryl 
hydrocarbon nuclear translocator–like protein which forms a heterodimer with the 
protein CLOCK and is involved in circadian rhythm regulation [Wolting and McGlade, 












by the binding of the ARNTL/CLOCK complex to the E-box sequences of circadian genes 
such as Period (Per) and Cryptochrome (Cry), thus promoting their transcription. Due to 
the cyclical nature of BPD, impairment in circadian rhythm patterns has often been 
implicated in the aetiology [Mansour et al., 2005]. Individuals undergoing a manic phase 
generally require less sleep or experience periods of insomnia, and those experiencing a 
depressive episode often have hypersomnia [Shi et al., 2008]. Sleep-deprived mice 
exhibit manic-like symptoms [Benedetti et al., 2008].  
 
ARNTL has also been found to be up-regulated in post-mortem brains of BPDI patients 
[Nakatani et al., 2006]. In a comprehensive study of BPD, Mansour et al. [2006] used 
separate study designs to identify predisposing regions of the genome. In the sub-cohort 
study, involving a case-parent trio study design, they found a positive association 
between two SNPs in ARNTL (rs7107287 and rs895682) and BPDI. Both of these SNPs 
are located in intronic regions of the gene. The case-control study design also revealed an 
association between ARNTL and BPDI patients. However, the SNP with the significant 
finding was rs1481892 and not the SNPs previously associated in the a case-parent trio 
study design [Mansour et al., 2006]. Haplotype analysis revealed an association between 
polymorphisms within ARNTL and another circadian gene, period homolog 3 (PER3), 
with BPD. However, after correction for multiple testing this association was no longer 














BDNF is located on chromosome 11p13, is 70 kb in size and has 11 exons [Sheikh et al., 
2010]. This gene has often been suggested in the aetiology of psychiatric disorders, as 
the protein it encodes is involved in the growth and maintenance of neurons within the 
CNS. Various extraneous factors such as stress and certain types of drugs affect the 
expression of this gene [Duman, 2002]. Interestingly, although this family of 
neurotrophins appear to be ubiquitously expressed in vertebrate nervous systems, 
similar sequences have not been detected in either of the C. elegans or D.melanogaster 
genomes suggesting that particular neurotrophic factors have functions in higher order 
neural activities such as learning, memory and behavior [Chao, 2000]. Several studies 
have investigated whether variants within BDNF incr ase risk for developing BPD. Of 
particular interest is the Val66Met (rs6265) functional polymorphism due to a G/A 
substitution [McHughen et al., 2010], in the prodomain of the protein [Bath and Lee, 
2006]. Although, the prodomain is cleaved from the mature protein, it is thought to be 
involved in the trafficking of BDNF. The Val66Met polymorphism has also been found on 
to be associated with BPD in several independent studies [Neves-Pereira et al., 2002; 
Sklar et al., 2002; Xu et al., 2010]. Most of these studies have found that BPD patients 
have a higher frequency of the valine (Val) allele. Subsequent studies did not show an 
association between the Val66Met polymorphism and the BPD phenotype [Green et al., 
2006; Vinberg et al., 2009]. However, Green et al. [2006] noted that the Val allele was 
significantly over-transmitted in individuals who presented with rapid cycling BPD. The 
Val66Met polymorphism has been shown to have an association with the human brain 
motor system and short-term learning in healthy individuals [McHughen et al., 2010]. 












hippocampal activation [Egan et al., 2003]. Also, individuals affected with BPD, 
possessing a Met allele, show a reduction in their temporal lobe grey matter volumes 
compared to those without a Met allele [McIntosh et al., 2007]. Similarly, Met carriers in 
a control population group, are more likely to have smaller hippocampal formations, 
[Pezawas et al., 2004; Bueller et al., 2006] as are individuals affected with major 
depression [Frodl et al., 2007]. 
 
1.5.4 ALDH1a1 
ALDH1A1, on chromosome 9q21.13, encodes an enzyme which is part of the aldehyde 
dehydrogenase family of proteins which consists of 16 distinct enzymes [Duester, 2001]. 
Aldehyde dehydrogenases are involved in the conversion of vitamin A (retinol) to its 
active form, retinoic acid, which in turn functions as a regulator of gene expression and 
plays an important role in the modulation of apoptosis [Palha and Goodman, 2006]. 
Retinoic acid has been postulated to play a role in the development of SCZ [Goodman, 
1998; LaMantia, 1999]. This is based on the observation that certain abnormalities that 
are characteristic of SCZ are also a feature of retinoid dysfunction. Some common 
characteristics include mental deficits and congenital abnormalities such as craniofacial 
and digital malformations. It has also been observed that several loci that have been 
previously linked to SCZ contain genes that are involved in the retinoic acid cascade. 
These include the genes retinoid X receptor β (RXRβ) on chromosome 6p21.3 and the 
retinoic acid receptor β (RARβ) on chromosome 3p24.3 [Goodman, 1998]. Therefore, 
genes involved in the retinoic acid pathway are often investigated in relation to SCZ 












(aldehyde dehydrogenase type 2) and SCZ in a Chinese population group [Wan et al., 
2009]. As BPD and  SCZ are thought to have some genetic overlap [Maier et al., 2005], it 
would be reasonable to consider ALDH1A1 as a possible candidate gene for BPD.  
 
1.5.5 A2PB1 
A2BP1 or ataxin-2 binding protein 1, predominantly expressed in both muscle and brain, 
encodes a protein which binds to the c-terminus of ataxin 2. A polyglutamine expansion 
in the gene ataxin-2 has been implicated the aetiology of spinocerebellar ataxia (SCA), a 
severe hereditary neurodegenerative disorder [Shibata et al., 2000]. The exact function 
of the A2BP1 gene is unknown [Ralser et al., 2005], however, it is thought to play a role in 
the splicing of downstream targets [Lee et al., 2009]. A translocation which results in a 
deletion in exon1 of the A2BP1 gene was previously observed in an individual with 
autism. This deletion resulted in decreased A2BP1 expression in the affected individual 
compared to controls [Martin et al., 2007]. Autism is a neuro-developmental disorder 
which shares some behavioural features with BPD and SCZ. Based on results from GWAS, 
it has been suggested, that these three psychiatric disorders, although distinct, share 
some genetic overlap [Carroll and Owen, 2009]. Hamshere et al. [2009] reported a strong 
association between a SNP in A2BP1 (rs4786811) and Schizoaffective Disorder. Also, two 
intronic SNPs within A2BP1, rs7204975 and rs10500336 have been found to be 
significantly associated (p-values= 0.001 and 0.018, respectively) with BPD in a German 













Myelin basic protein or MBP encodes a protein which composes approximately 30% of 
the myelin membrane surrounding neuronal tissue [Chambers and Perrone-Bizzozero, 
2004]. This gene is located on chromosome 18q22-q23 [Kamholz et al., 1987]. 
Myelination continues within the human brain, with the culmination of myelinogenesis 
occurring in the frontal and temporal lobes in late adolescence and early adulthood 
[Chambers and Perrone-Bizzozero, 2004]. Interestingly, myelination of these lobes 
coincide with the supposed time of disease onset in SCZ patients [Chambers and 
Perrone-Bizzozero, 2004] which is also the age of disease onset for some of the 
individuals affected with BPD [Miller, 2006]. It is therefore likely that a relationship 
between myelination and the development of such psychiatric disorders might exist 
[Chambers and Perrone-Bizzozero, 2004]. Genome-wide microarray studies involving 
the post-mortem brains of BPD and SCZ patients have revealed significant differential 
expression of genes involved in myelination [Tkachev et al., 2003; Hakak et al., 2001]. 
Five genes which are involved in the development and maintenance of the myelin 
membrane were found to be downregulated in SCZ brains when compared to controls. 
Thus, abnormalities in myelination may be an aetiological factor for BPD based on the 
purported genetic overlap between BPD and SCZ. 
 
The GWAS conducted by Sklar et al. [2008] found an association between an intronic SNP 
(rs12967023) in MBP and individuals affected with BPDI. This association has not been 













AK3L1 or adenylate kinase 3-like 1 (also known as AK3 and later renamed to AK4) 
encodes a member of the adenylate kinase family of enzymes. This family of kinases 
consists of five isozymes [Noma et al., 2001] and are primarily involved in the regulation 
of adenine and guanine bases [Yoneda et al., 1998]. The protein encoded by AK3L1 has 
been shown to be localised to the mitochondrial matrix and is classified as a guanosine 
triphosphate: adenosine monophosphate (GTP:AMP) phosphotransferase which is 
involved with the phosphorylation of mitochondrial AMP (required for cellular 
respiration) [Noma et al., 2001; Dzeja and Terzic, 2009]. Expression studies have 
revealed that AK3L1 is highly expressed in heart and skeletal muscle, liver and only 
weakly expressed in the brain [Noma et al., 2001]. AK3L1, on chromosome 1p31.3, has 
not previously been associated with any psychiatric disorder. However, the GWAS 
conducted by the WTCCC found that an intronic SNP within AK3L1 (rs4916031) was 
strongly associated with BPD (p-value 9.8 x 10-5) [Stratton, 2007]. 
 
1.5.8 GSK3β 
GSK3β encodes glycogen synthase kinase 3 beta which is involved in the phosphorylation 
of serine and threonine. This protein is involved in the WNT signalling pathway 
[Cruceanu et al., 2009] which has an important function in cell fate and development 
[Logan and Nusse, 2004]. Expression of genes from the WNT signalling pathway has 
been previously found to be dysregulated in affected individuals with BPD [Matigian et 
al., 2007]. In a genome-wide expression study, GSK3β was found to be downregulated in 
the post-mortem brains of individuals affected with BPD [Nakatani et al., 2006]. 












teenagers who have committed suicide (which is the most severe consequence of BPD) 
compared to normal controls [Pandey et al., 2009]. Recently, it was noted that 
polymorphisms within GSK3β (rs6438552) are associated with regional grey matter 
volumes in patients with major depressive disorder [Inkster et al., 2009]. GSK3β is also 
an important regulator of the proteins involved in the circadian rhythm pathway [Sahar 
et al., 2010]. Lithium, the first line treatment for BPD, as well as the mood-stabiliser, 
sodium valproate, are thought to inhibit GSK3β [Klein and Melton, 1996; Nishiguchi et al., 
2006]. The -50 T/C polymorphism (rs334558), located in the promoter region of GSK3β, 
has been found to have an association with response to lithium treatment for BPD and 
depression [Benedetti et al., 2005; Adli et al., 2007]. This polymorphism has also been 
associated with age of onset for BPD patients, which is an indicator of phenotype severity 
[Benedetti et al., 2004]. Therefore, GSK3β seemed to be a reasonable candidate in the 
aetiology of BPD [Nishiguchi et al., 2006]. 
 
 1.5.9 ANK3 
This gene, located on chromosome 10q21, encodes the protein ankyrin 3. Ankyrins are 
thought to be involved in the linking of membrane proteins to the cell cytoskeleton and 
are involved in cellular processes such as motility and proliferation [Kordeli et al., 1995]. 
Ankyrin 2 (ANK2) obtained a CFG score of 5 in the research conducted by Le-Niculescu et 
al. [2008]. ANK3 is neural-tissue specific and is found at the Node of Ranvier where it is 
thought to play a role in maintenance of cell-adhesion molecules and ion channels 
[Kordeli et al., 1995]. The first study to implicate ANK3 as having an association with BPD 












was rs9804190 which is located in an intronic region of the gene. Subsequently, a meta-
analysis of three GWAS found an association between a SNP within this gene 
(rs10994336) and BPD [Ferreira et al., 2008]. Furthermore, several other studies were 
able to replicate this finding in independent samples [Scott et al., 2009; Smith et al., 
2009; Schulze et al., 2008]. 
 
1.5.10 CACNA1C 
This gene encodes the alpha 1C subunit of the L-type voltage-gated calcium channel and 
is located on chromosome 12p13.3 [Lory et al., 1997]. Voltage-gated calcium channels 
are responsible for calcium influx, which in turn mediate cellular processes such as 
contraction, secretion, neurotransmission and gene expression. There are ten members 
of the voltage-gated calcium channel family, located in different cell types [Catterall et al., 
2005]. Calcium channel, voltage dependent, alpha 1a subunit (CACNA1A) and calcium 
channel, voltage dependent, beta 2 subunit (CACNB2) had CFG scores of 6 and 5.5, 
respectively [Le-Niculescu et al., 2008]. CACNA1C has been shown to be associated with 
BPD in a meta-analysis involving 3 GWAS [Ferreira et al., 2008]. The particular SNP 
(rs1006737) which was associated in the study was also found to lead to an increased 
risk of developing major depression and SCZ [Green et al., 2009]. This SNP, located in an 
intron, has also been found to be a risk factor for developing a more severe depressive 
phenotype and insomnia [Casamassima et al., 2010]. In another study, rs1006737 was 
found to have an association with cerebral grey matter volume. Healthy individuals 
without any history of mental disorders, carrying the A allele of rs1006737 had larger 












[Kempton et al., 2009]. CANB1 (Calcium channel, voltage-dependent, beta-1 subunit) was 
shown to be upregulated in post-mortem BPDI brains [Nakatani et al., 2006]. The 
evidence therefore points to CACNA1C as a possible candidate gene for BPD. 
 
1.6 Aims and Objectives 
The first aim of the present investigation was to determine whether SNPs, within ten 
selected candidate genes, have an association with BPD. The second aim was to 
determine whether the genotypes of these variants were associated with brain imaging 
volumes. The objectives were the following: 
 
i) To select a list of candidate genes with very strong evidence of involvement in 
BPD 
 
ii) To identify a cohort of individuals from the BPD registry at the University of 
Cape Town (UCT) 
 
iii) To genotype the candidate genes using a PCR-based technology 
 
iv) To analyse the genotyping data with the appropriate statistical methods 
 
v) To obtain brain imaging data of a subset of the larger cohort and to perform 



























KLF12 13q22.1 8 rs9600160 intron G/A 
Non-
functional 
ARNTL 11p15.2 8 rs7107287 intron G/T 
Non-
functional 
BDNF 11p14.1 8 rs6265 exon 2 C/T Missense 
ALDH1A1 9q21.13 8 rs1888202 intron G/C 
Non-
functional 
A2BP1 16p13.3 7.5 
rs7204975 intron C/T 
Non-
functional 
rs10500336 intron C/T 
Non-
functional 
MBP 18q23 7.5 rs12967023 intron C/T 
Non-
functional 
AK3L1 1p31.3 7 rs4916031 intron G/A 
Non-
functional 
GSK3β 3q13.3 7 rs334558 promoter C/T 
Non-
functional 
ANK3 10q21 NA rs9804190 intron C/T 
Non-
functional 
















Chapter 2: Materials and Methods 
 
2.1 BPD Cohort Description  
Ethics approval for the “Genetics of Bipolar Disorder” research project was first granted 
by UCT’s Research Ethics Committee in 1996 (REC Ref 081/1996). The aim of the project 
was to build a BPD archive, predominantly consisting of families, for the purpose of 
investigating the genetic complexities of the disorder. Between 1997 and 1999, 
individuals were recruited to the project from Gauteng, Free State, Eastern Cape and 
Western Cape. The cases were diagnosed with the Structured Clinical Interview for the 
DSM-IV (SCID) applied by a qualified psychiatric research nurse and verified by a 
psychiatrist. As the name suggests, SCID is a semi-structured questionnaire which allows 
for the diagnosis of DSM-IV axis disorders. Criteria for inclusion included an index 
patient and an available first-degree relative, both with a BPDI or BPDII diagnosis. The 
BPDI diagnosis was subsequently confirmed by a qualified psychiatrist. Interaction with 
healthcare professionals, advocacy groups and genealogical assessment resulted in the 
further recruitment of family members with a diagnosis of BPDI, BPDII, or recurrent 
MDE. 
 
More recently, participants have been recruited from the outpatient unit at Valkenburg 
Hospital, Observatory, in Cape Town. All individuals were recruited when stable (not 
experiencing a manic or depressive episode), and blood samples were obtained with 













2.1.1 Cohort Description for Case-Control Analysis 
For the current study, updated ethics approval was obtained in June 2009 (REC Ref 
229/2009). The research cohort, a subset of the larger BPD cohort, consisted of: i) an 
experimental group consisting of 224 individuals specifically diagnosed with BPDI 
(cases), and ii) 202 background population controls. The cases consisted of individuals of 
Mixed Ancestry and Caucasian ethnicity. A select number of cases were from the same 
family. These families were sampled for previous linkage studies. The inclusion of 
related cases in case control studies, if used appropriately, have been shown to increase 
study power as related individuals are thought to carry a higher frequency of disease risk 
alleles as compared to unrelated cases [Thornton and McPeek, 2007; Yoo et al., 2007]. 
The controls were selected from the Division of Human Genetics database. Most of these 
individuals were the unaffected spouses of individuals with other genetic disorders such 
as non-polyposis colorectal cancer and retinitis pigmentosa. All of the controls were 
unrelated and of unknown phenotype in terms of psychiatric disorders. The aim was to 
have a matched case–control design whereby controls were similar in terms of gender 
and ethnicity to case individuals. An advantage of having a matched case-control design 
is that a much smaller sample size is required to detect statistical significance [Mann, 
2003] and that potential confounders such as gender and ethnicity are adjusted for 
[Niccolai et al., 2007]. A disadvantage is that if controls are too closely matched they do 
not represent the general population [Mann, 2003]. 
2.1.2 Cohort Description for Brain Imaging Analysis 
The current study involved an investigation of a cohort of individuals affected with BPD, 
towards the identification of genes which may predispose to the condition. In addition, 













identifying potential endophenotypes which could be investigated genetically. In this 
regard, a subset of the BPD cohort was investigated by MRI brain imaging and genetics. 
The brain imaging analysis was done as part of the “Neuroimaging the Effects of 
Mindfulness Training in Bipolar Disorder” research project, carried out by the Department 
of Psychiatry (UCT). Separate ethics approval was obtained for this study (REC Ref 
078/2009). For recruitment of participants, the study was advertised at the University of 
Cape Town, in newspapers and at specialized seminars. Participants were also recruited 
from the existing cohort and referrals from other health professionals. Imaging was 
performed for a subset (n=22) of the 224 BPDI case group. 
 
2.2 DNA Isolation and Quality Determination 
DNA was isolated, from blood samples, using the Gentra PuregeneTM DNA Isolation Kit 
(Gentra Systems, Minneapolis, MN, USA). The protocol involved the following steps: the 
lysis of red blood cells (RBCs) and nucleated cells, protein precipitation, DNA 
precipitation, recovery, and rehydration. Following rehydration in DNA hydration 
solution, the isolated DNA was stored at either -20°C (for short-term storage) or -80°C 
(for long term storage). A more detailed protocol is included in Appendix 2. 
 
The integrity and quality of the DNA samples were verified using two methods: 
(i) Spectrophotometric quantification  
(ii) Agarose gel electrophoresis 
For quantification, the concentrations of undiluted, stock DNA samples were determined 
using a Nanodrop 1000 spectrophotometer (Nanodrop Technologies Inc., Wilmington, 













Johannesburg, SA) to a working concentration of 100ng/µl. For agarose gel 
electrophoresis, a volume containing 200ng of DNA together with loading buffer 
(Fermentas Life Sciences, Hanover, USA) was loaded onto a 1% agarose gel (Appendix 
3). To estimate integrity of DNA fragments, the first lane of the gel was loaded with a 
100bp molecular weight marker (MWM) (Fermentas Life Sciences, Hanover, USA) 
(Appendix 3). To enable DNA visualization, 30ng of ethidium bromide (EtBr) (Sigma, 
England), a DNA intercalating agent, was added to the agarose prior to solidification. Gel 
electrophoresis was carried out in a gel tank with 1x Tris Borate EDTA (TBE) (Appendix 
3) electrophoretic buffer, at 160V for approximately 30 minutes. Thereafter, it was 
placed in the Uvipro Gold transilluminator (UVITec, Cambridge, UK) for the illumination 
and image capture of the DNA fragments.  
 
2.3 Gene and SNP Selection, Primer Design and Synthesis  
2.3.1. Gene and SNP selection 
In 2008, Le-Niculescu et al., based on a CFG approach (see Chapter 1: Introduction, pg 
32), constructed a prioritised candidate gene list for BPD. The top eight genes on this list 
were chosen to be genotyped in the current study. Each of these genes obtained a CFG 
score of seven and above (12 being the maximum). The CFG score is based on previous 
evidence, therefore SNPs were chosen based on their significant association to BPD in 
independent studies. The remaining two genes, ANK3 and CACNA1C and their respective 
SNPs, were chosen based on their association to BPD in a GWAS [Baum et al., 2008; 
Ferreira et al., 2008]. Table 5 contains all of the candidate genes, their respective SNPs 













Table 5: Selected candidate genes, respective SNPs and CFG scores  
Gene SNP CFG Score 
KLF12 rs9600160 8 
ARNTL rs7107287 8 
BDNF rs6265 8 






MBP rs12967023 7.5 
AK3L1 rs4916031 7 
GSK3β rs334558 7 
ANK3 rs9804190 - 
CACNA1C rs1006737 - 
 
2.3.2 External Primer Design 
The sequences of each of the ten candidate genes (KLF12, ARNTL, BDNF, ALDH1a1, 
A2BP1, MBP, AK3L1, GSK3β, ANK3, and CACNA1C) were obtained from NCBI 
(http://www.ncbi.nlm.nih.gov) and Ensembl (http://www.ensembl.org/index.html) 
databases. The sequence of each of the genes was then annotated to specify the location 
of the exons, coding sequence, start/stop codons and SNPs. This was accomplished using 
the ANNOTV9 annotation programme [Rebello, 2006, Unpublished], which utilises the 
Perl scripting language [Wall, 1987]. 
 
Once the regions of interest were identified, suitable primers were designed to amplify 
these sequences. The web-based program, Primer3 
(http://fokker.wi.mit.edu/primer3/input.htm), which searches for possible primer 
sequences from the nucleotide sequence, was used for this purpose. The selected 













(http://www.idtdna.com/analyzer/Applications/OligoAnalyzer), a program which 
predicts any secondary structures such as primer dimers and hairpins which may occur. 
Secondary structures greatly reduce the efficiency of the PCR reaction [Singh et al., 
2000]. To ensure the primer only binds to the sequence of interest, the primer sequences 
were checked against a database, NCBI BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
All the primer sequences are contained in Table 6. 
 
The oligonucleotides were synthesised using the Oligo 1000M DNA Synthesiser v4.20 
(Beckman Instruments Inc., Department of Molecular and Cell Biology, UCT).The primer 
stock solutions were diluted with Sabax distilled water (dH2O) (Adcock Ingram, 
Johannesburg, SA) to a working concentration of 20µM. 
 
2.4 Polymerase Chain Reaction (PCR) 
The target regions of interest in each of the candidate genes were amplified using PCR. 
To obtain the optimal annealing temperature (Ta), a temperature gradient was used to 
assay all of the primer pairs. The PCR reaction consists of deoxynucleotide triphosphates 
(dNTPs), Taq Polymerase, Taq Buffer, DNA, forward primer, reverse primer and distilled 
water (dH2O). Based on the optimal Ta for each primer pair and amplicon size, certain 
primer sets were multiplexed together in one PCR reaction. Multiplexing of primers 
allows for the efficient usage of reagents and resources. A negative (water) control was 
included, which consisted of all the reaction components except DNA, to ensure that any 




















Primer Sequence  







KLF12 Foward 18 acgtagcagcaccagtct 55.6 56.2 
180 
 Reverse 21 gagagagtagcaagccaaatg 47.6 53.4 
ARNTL Foward 18 gaagccatgagtctagca 50 51.5 
237 
 Reverse 18 gtagaaccctggacagtt 50 51 
BDNF Foward 24 caagaggcttgacatcattggctg 50 58.5 
338 
 Reverse 24 ccgacatgtccactgcagtctttt 50 59.6 
ALDH1A1 Foward 19 tctatagttctgaccccac 47.4 50.2 
394 
 Reverse 18 tttctcagctacgccatg 50 52.3 
A2BP1(A) Foward 17 tctatagttctgaccccac 47.1 47.7 
192 
 Reverse 19 tttctcagctacgcc tg 42.1 47.5 
A2BP1(B) Foward 20 cgtggtctcttctcttgttc 50 52.8 
250 
 Reverse 20 ggcacaacaggctatacaga 50 54.5 
MBP Foward 18 cttggtctcagtgaagcc 55.6 52.9 
170 
 Reverse 19 gaatcgtgtcctggttgtg 52.6 53.6 
AK3L1 Foward 20 cagactggcttgttaccctc 55 55.3 
155 
 Reverse 20 ggatagaggttgagagctgg 55 54.3 
GSK3β Foward 22 cgattcccagacgcctgttacg 59.1 60 
302 
 Reverse 18 tcaggaagtgtccgcgct 61.1 59.4 
ANK3 Foward 18 gccagctaacaatgaacc 50 51.3 
227 
 Reverse 21 gtcatatcctagtcccgattc 47.6 51.8 
CACNA1C Foward 18 gttccattccatctcagc 50 50.5 
220 













PCR was carried out on a PxE 0.2 Thermal cycler (Thermohybaid, Middlesex, UK) at the 
conditions stipulated in Table 7. Once completed, the PCR products were maintained at 
a temperature of 4°C until required for downstream processes. 
 
To determine whether amplification had occurred, the PCR products together with 
loading buffer were resolved on a 2% agarose gel (Appendix 3), run at 160V, for 
approximately 40 minutes. The current was set at the maximum value (approximately 
110 MA). MWM (100bp) (Appendix 3) was added to the first lane of the gel. The gel was 
exposed to UV light in the Uvipro Gold transilluminator (UVITec, Cambridge, UK) and the 
resultant image captured.  
 
Table 7: PCR cycling conditions 
Stage Temperature (°C) Duration No. of Cycles 
1 94 5 minutes 1 
 
2 
94 30 seconds 
 
30 
Ta 30 seconds 
72 30 seconds 
3 72 7 minutes 1 
 
 
2.5 SNaPshot PCR 
SNaPshot PCR is a SNP genotyping method and is an extension of the basic PCR process. 
Internal primers were designed to bind 5’ or 3’ of the SNP of interest in each of the 
amplified candidate genes. The use of this technique requires SNaPshotTM multiplex 
ready reaction mix (Applied Biosystems, Warrington, UK) which contains fluorescently-













buffer. The Taq polymerase catalyses the single base extension of the unlabelled primers 
by incorporating the complementary differentially-labelled ddNTP [ABI Prism 
SNaPshotTM Multiplex Kit Protocol, Applied Biosystems] (See Figure 1). The ddNTPs lack 
an acceptor 3’ hydroxyl group. Therefore, the AmpliTaq polymerase is unable to add an 
additional base to the ddNTP and extension is terminated. The end results of this 
technique are peaks which represent the alleles at a particular SNP. Table 8 indicates the 
dyes attached to each of the ddNTPs and the resulting peak colours. 
 
 




Table 8: Dyes assigned to each of the ddNTPs 
ddNTP Dye Colour 
Adenine (A) dR6G Green 
Cytosine (C) dTAMRATM Black 
Guanine (G) dR110 Blue 













2.5.1 SNaPshot PCR Internal Primer Design 
The criteria for SNaPshot internal primers were the same as those stipulated for the 
external primers except that only one primer (either forward or reverse) was needed for 
SNaPshot PCR. The primers were designed by choosing consecutive bases immediately 5’ 
or 3’ of the SNP of interest. However, for the purposes of multiplexing, each of the 
primers needed to be of a different length to ensure that the appropriate alleles could be 
called for the respective gene and there would be no overlap in the SNaPshot product. 
Therefore, random tails of nucleotide repeats were attached to each of the primers. 
Another way of ensuring that primers could be multiplexed, even if two primers were the 
same length, was to ensure that those primers had different expected peak colours. A 
local BLAST search, using the sequence alignment program, BioEdit Sequence Alignment 
Editor 7.0.0 (Tom Hall, Isis Pharmaceuticals, Inc.), was done to ensure that the primers 
did not hybridise to one another. The sequences of the internal primers are displayed in 
Table 9. 
 
Internal primers (25nmole) were synthesized by IDT® 
(http://eu.idtdna.com/order/order.aspx) and were received in a lyophilized form. To 
prevent contamination, each of the primers were desalted and quality was tested by 
mass spectrometry. Subsequently, the primers were resuspended with TE (10mM Tris 
pH8.0, 1mM EDTA) to a stock concentration of 100µM. Working solutions of 20µM 
primer concentration, in a total volume of 50µl, were made by the addition of Sabax 













Table 9: SNaPshot internal primer sequences for genotyping of SNPs within candidate genes 
Gene SNP Primer Direction Primer Sequence Expected Primer Length Peak Colours 
KLF12 rs9600160 Forward gagtgttaggaattgattagatgt A/G 24 Green/Blue 
ARNTL rs7107287 Forward agctagcaatctgatgtgtt G/T 20 Blue/Red 
BDNF rs6265 Reverse 1ctctctctctctccaacagctcttctatca C/T 30 Black/Red 
ALDH1A1 rs1888202 Forward tagtacgtgattaagaagtcctgcatttaa C/G 30 Black/Blue 
A2BP1(A) rs7204975 Forward cacacacacacacacacaatagtcagcaggaaaca C/T 35 Black/Red 
A2BP1(B) rs10500336 Reverse ggctgttactaccactatcttaa C/T 23 Black/Red 
MBP rs12967023 Reverse catcattgaagccgcacttggtttt C/T 25 Black/Red 
AK3L1 rs4916031 Reverse gaacaggaagctctaaaag A/G 19 Green/Blue 
GSK3β rs334558 Forward ttagttagttagttagtatcctcacacagagcagc C/T 35 Black/Red 
ANK3 rs9804190 Forward cctcaagaaggtaaggaaa C/T 19 Black/Red 
CACNA1C rs1006737 Forward tagtagtagtagtagtagtagcattccatctcagcccgaa A/G 40 Green/Blue 













2.5.2 Sap and ExoI Clean-up of PCR Products 
Before SNaPshot PCR could be carried out, unincorporated dNTPS and primers from the 
initial PCR needed to be removed, to ensure that there was no interference with the 
genotyping process [ABI Prism SNaPshotTM Multiplex Kit Protocol, Applied Biosystems]. 
Shrimp alkaline phosphatase (SAP) (Promega, USA) allows for the dephosphorylation of 
the 5’ phosphates of DNA. Exonuclease I (ExoI) (Biolabs, New England) catalyses the 
removal of bases from single-stranded DNA in a 3’-5’ direction, promoting the 
degradation of the excess single-stranded primers 
(http://www.neb.com/nebecomm/products/productm0293.asp).  
 
The purification process was carried out on an Applied Biosystems thermal cycler (Gene 
Amp® PCR System 9700) at the conditions listed in Table 10 and using the reagents in 
Table 11. Firstly, a master mix was made up with the SAP, ExoI and dH2O and aliquoted 
into each well of the segmented 96-well PCR Microplate (Axygen Scientific, California, 
USA). The PCR product was then aliquoted into each respective well. Wells were sealed 





Table 10: Conditions for Sap and ExoI purification 
Temperature (°C) Duration 
37 1 hour 























  Singleplex Reactions Multiplex Reactions 
SAP 5 units 1 unit 1.5 units 
ExoI 2 units 2 units 2 units 
PCR 
Product 
- 5 µl 5 µl 
dH2O - 13.9 µl 13.4 µl 
Total 
Volume: 
- 20 µl 20 µl 
 
2.5.3 SNaPshot PCR Conditions 
Multiplex SNaPshot reactions, whereby an equal ratio of the respective primers were 
pooled, were carried out on 96-well PCR Microplates (Axygen Scientific, California, USA). 
For each SNaPshot reaction, a negative water control was also included. The control was 
included to ensure that the results obtained from the sample reactions were not a result 
of any form of contamination. This control contained all the components of the multiplex 
SNaPshot reaction but lacked any purified PCR sample. Table 12 illustrates the volumes 
of the components of a SNaPshot reaction. The samples were loaded into a Applied 
Biosystems thermal cycler (Gene Amp® PCR System 9700) and run at the conditions 














Table 12: The components of the SNaPshot PCR reaction 
Reagents Reaction Volumes (µl) 
 Singleplex Reactions Multiplex Reactions Negative Water Control 
Reaction Mix 1 1 1 
Internal Primers 1 1 (pooled) 1 
PCR Product 1 5 - 
dH2O 7 3 8 




Table 13: Conditions for SNaPshot PCR 









2 4 ∞  
 
 
2.5.4 Post- SNaPshot SAP Treatment 
Before the samples were genotyped, all the unincorporated ddNTPs needed to be 
removed by the phosphatase action of SAP. If left untreated, the ddNTPS would co-
migrate with the products of interest. Thus, the removal of the phosphatase groups of 
these nucleotides hindered the movement and prevented any interference [ABI Prism 














One unit of SAP was added to the SNaPshot PCR products. The samples were then loaded 
into a Applied Biosystems thermal cycler (Gene Amp® PCR System 9700) at the 
conditions listed in Table 10.  
2.5.5 Capillary Electrophoresis on ABI PRISM 
Purified SNaPshot reactions were resolved on the ABI prism 3100 Genetic Analyzer 
(Applied Biosystems, CA, USA). A mixture of SNaPshot product, HiDi formamide (Applied 
Biosystems, Warrington, UK) and GeneScan-120 Liz size standard (Applied Biosystems, 
CA, USA) (Appendix 4) were loaded into a 96-well PCR Microplate (Axygen Scientific, 
California, USA). The HiDi functions to maintain the double-stranded DNA in a denatured 
state and the Liz allows for the sizing of the allele peaks. The dye set was set at E5, the 
analysis method at GeneScan-120 Liz and the run module at SNP36_POP4. 
2.5.6 Analysis of Results 
The genotyping results were analysed by the Genemapper 3.0 Genescan Software 
(Applied Biosystems, CA, USA). This software provides automated sizing of peaks and 
was used for the analysis of each of the SNPs. It generated a table with all the alleles and 
user-specified process-based quality values which relayed the integrity of the data. Bins 
which corresponded to a particular base-pair range for a specific allele were defined. 
Software algorithms determined whether peaks were representative of an allele at that 
position.  
 
2.6 Genotype Validation 













2.6.1 PCR of DNA Samples for Cycle Sequencing 
A subset of the samples were chosen based on the results shown by SNaPshot PCR. These 
contained all possible genotypes (homozygous and heterozygous) for each of the 11 
SNPs. PCR was carried out on the selected samples using the same cycling conditions as 
in Table 7. Amplified products were resolved on a 2% agarose gel (Appendix 3) 
together with loading buffer. MWM (Appendix 3) was added to the first lane of the gel. 
The gel was run for approximately 40 minutes and placed in the Uvipro Gold 
transilluminator (UVITec, Cambridge, UK) for visualisation and image capture purposes. 
PCR products of adequate band intensity were used for the sequencing reaction. 
2.6.2 Cycle Sequencing  
Cycle sequencing was done on amplified products using the reagents listed in Table 14. 
Cycle sequencing was carried out on an Applied Biosystems thermal cycler (Gene Amp® 
PCR System 9700) at the conditions displayed in Table 15. Most SNPs were sequenced 
using the forward primer. However, ARNTL rs7107287, BDNF rs6265 and CACNA1C 
rs1006737 were sequenced using the reverse primer as these SNPs were located 
towards the 5’ end of the respective amplicons. Typically, peaks at the start (5’end) of a 
sequence are undistinguishable. Therefore, when sequenced with the forward primers, 
the ARNTL rs7107287, BDNF rs6265 and CACNA1C rs1006737 SNPs were not 
identifiable. 
2.6.3 Ethanol Precipitation 
The DNA was purified from the reaction mixture by precipitation with ethanol. This step 
removed any unincorporated ddNTPs which could potentially interfere with the start of 



















BigDye Terminator Mix 2.5x 1 
Sequencing Buffer 5x 4 
Forward/Reverse Primer - 0.5 
PCR product - 2 
dH2O - 12.5 




Table 15: Cycle sequencing PCR conditions 
Temperature 
(°C) 
Duration No. of Cycles 
96 5 min  
96 30 sec  
25 50 15 sec 
60 4 min 
 
 
2.6.4 Capillary Electrophoresis on ABI Prism 
The sequencing samples were run on the ABI Prism 3130XL Genetic Analyzer (Applied 
Biosystems, CA, USA). A volume of 5µl of the sequencing sample was added to 8µl HiDi 














2.6.5 Analysis of Results 
The sequences of each of the candidate genes were visualised in the BioEdit Sequence 
Alignment Editor version 7.0.0 (Tom Hall, Isis Pharmaceuticals, Inc.). This allowed for 
the identification of the genotype of the SNP of interest. 
 
2.7 Statistical Analysis 
2.7.1 Genotype Frequencies, Hardy-Weinberg Equilibrium 
Calculations and Logistic Regression with R 
Genotype frequencies for all of the SNPs (cases and controls), Hardy Weinberg 
Equilibrium (HWE) calculations (controls only), and case-control association were 
determined using the statistical environment R (http://www.R-project.org). The method 
used to determine whether there was an association between disease status and 
genotype frequency, was logistic regression. This method fits a statistical model to a data 
set whereby the dependent variable is dichotomous and the independent variable is 
either continuous or discrete. In this instance, the dependent variable was disease 
affection status (i.e. case or control) and the independent variable were the three 
genotypes for a particular SNP. The logistic regression test computes the odds ratio 
which is defined as the probability of an event occurring over the probability of the event 
not occurring [Munro, 2001]. The z-test value is the test statistic and lower and upper 
confidence intervals are specified. As more than one statistical analysis was performed 
(disease status versus SNP), the Bonferroni correction was implemented for multiple 
testing, to avoid spurious significance. Therefore, the “corrected” significance level was 














2.7.2 MQLS (adjusting for relatedness) and Pedstats 
A number of the cases belonged to the same family. This presented both an advantage 
and challenge in the statistical analysis. The advantage is that affected individuals within 
the same family are expected to have a higher frequency of the disease causing allele 
which may be easier to detect than in unrelated cases. Therefore, the power of the 
association is increased as well as the effective sample size. The challenge is that the 
relatedness amongst cases needs to be adjusted for in the analysis [Thornton and 
McPeek, 2007]. The MQLS method is able to perform basic case-control analysis with the 
addition of adjusting for related individuals. For this analysis, genotyping results of 
affected individuals were incorporated into a pedigree file to specify relationships within 
families. To ensure quality of pedigree data, i.e. whether there were any errors within the 
pedigree file, the program Pedstats was used [Wigginton and Abecasis, 2005].  
 
2.8 Neuroimaging of Subset of Cohort 
T1 weighted MRI scans were obtained using a high resolution Siemens Magneton Allegra 
3T scanner at the Cross Universities Brain Imaging Centre (http://sun.ac.za/cubic). 
Hippocampal and total intracranial volumes, from 22 individuals affected with BPDI, 
were obtained using the automated software package Freesurfer (version 5.0.0) [Fischl 
et al., 2002] (http://surfer.nmr.mgh.harvard.edu/) running at the Center for High 
Performance Computing in Cape Town (http://chpc.ac.za). Hippocampal volumes were 














2.8.1 Statistical Analysis of Neuroimaging Results 
Analysis of variance (ANOVA) was used to determine whether there were any 
associations between imaging measures and genotypes. The null hypothesis for ANOVA 
is that the means between two or more groups are the same, therefore, the alternate 
hypothesis is that means between groups are significantly different. This statistical 
measure tests whether the “between group” variation is greater than the “within group” 
variation. If this is found to be true, it suggests that the means between groups are 
different. The F-value represents the ratio of the “between group” and “within group” 
variance. ANOVA is a fairly robust statistical test, requiring that the dependent variable 
be continuous (e.g. imaging measure) and the independent variables be categorical (e.g. 
SNP genotype). ANOVA has the added advantage of being able to include more than one 
independent variable in a single test. The use of ANOVA requires that three assumptions 
be met, namely, i) the dependent variable is normally distributed, ii) there is 
independence between groups, iii) and variances are equal (homogeneity of variance) 
[Munro, 2001]. The Shapiro-Wilk test was used to ensure a normal distribution for the 
following measures: left and right hemisphere hippocampal volumes and intracranial 
volumes. In instances where the data was non-normally distributed, the non-parametric 
Kruskal-Wallis test was utilised, which compares the mean ranks in each group[Munro, 














Chapter 3: Results 
3.1 BPD Cohort Description  
To date, the BPD cohort consists of 919 individuals from 221 families. A total of 550 
females and 366 males (three of unknown gender) have been recruited. The cohort 
consists of individuals from the Caucasian (British, Afrikaner, Portuguese, Greek, and 
Ashkenazi Jewish), Mixed Ancestry, Indian and African population groups. Figure 2 
represents the distribution of these ethnic groups within the cohort. The most prevalent 
diagnoses present in the archive includes mood disorders (BPDI, BPDII, MDE) (with 
BPDI being the primary diagnosis), Borderline Personality Disorder (PD), Post Traumatic 
Stress Disorder (PTSD) and Alcohol Abuse. Figure 3 indicates the relative distribution of 
most of the diagnoses present in the BPD archive.   
 
 





























Figure 3: Distribution of most prevalent phenotypes of BPD cohort 
 
 
3.1.1 Cohort Description for Case-Control Analysis 
In terms of cohort size, the aim was to have an equal number of cases and controls, with 
the control samples similar to cases in terms of gender and ethnicity. However, the final 
cohort consisted of 224 cases affected with BPDI and 202 background control samples. 
Within the case group, 93 individuals were derived from 35 BPD families and 131 were 
singletons (i.e. the only person to be represented in the cohort, from a particular family). 
Figure 4 represents the numbers of females and males and Figure 5 shows the number 
of individuals from each of the ethnic groups, within the study cohort. A proportion of 
controls were of unknown gender and age. There was more than two times the number 
of Caucasians as there were Mixed Ancestry individuals in the control group. Thus, 
controls were not similar to the case group in terms of gender and ethnicity. However, 




















































































3.1.2 Cohort Description for Brain Imaging Analysis 
The imaging cohort consisted of 22 individuals affected with BPD, 20 of who were female 
and two were males. A total of 14 individuals were Caucasian and eight individuals were 
of Mixed Ancestry ethnicity.  
 
3.2 DNA Quality Determination 
To determine the quality of DNA, samples were quantified by means of 
spectrophotometry and agarose gel electrophoresis. Samples had to have a 
concentration of greater than 50ng/µl to be deemed satisfactory for further analysis. 
DNA quality was determined by resolution on a 1% agarose gel (Appendix 3). Bands 
which appeared thick and bright at the top of the lanes were indicative of non-degraded, 
good quality DNA. This was shown in lanes 4, 5, 7, 8, and 9 (Figure 6). Degraded DNA 
samples appeared as a smear, as can be seen in lanes 1, 2, 3 and 6 (Figure 6).  
 
 
Figure 6: Integrity gel of genomic DNA. Lane M: 100bp MWM, Lanes 1-9: Genomic 

















3.3 Gene and SNP Selection, Primer Design and Synthesis  
Candidate genes investigated in this study were selected based on results from the CFG 
method [Le-Niculescu et al., 2008] and the most significant findings in GWAS, related to 
neuropsychiatric disorders and BPD specifically. The specific SNPs that were finally 
chosen per gene were those that had been reported with significant results from 
previous GWAS and candidate-gene association studies. Primers were designed to 
produce a PCR product incorporating the specific (respective) SNP for each gene. 
 
3.4 Polymerase Chain Reaction (PCR) 
3.4.1 PCR Optimisation 
The optimum Ta for each PCR reaction was determined by a temperature gradient, 
whereby 12 reactions were carried out at different temperatures ranging from 50°C to 
62°C. The Ta for each of the 12 reactions is displayed in Appendix 6. A separate 
temperature gradient was carried out for each primer pair. Figure 7 indicates the 
temperature gradient for KLF12 rs9600160. Non-specificity is seen at lower 
temperatures (lanes 1-4) and little/no product at higher temperatures (lanes 11 and 12). 
The optimum annealing temperature for this reaction was chosen as approximately 58°C 
as there was ample product and an absence of non-specificity. Similarly, for the other 
primer pairs, an optimum Ta was chosen based on the best product band intensity and a 
lack of non-specific products (See Appendix 7 for additional gel pictures). These values, 

















Figure 7: KLF12 rs9600160 (180bp) Temperature Gradient. Lane M: 100bp MWM. 
Lanes 1-12: PCR products amplified at varying annealing temperatures as 




Table 16: Optimal annealing temperature determined for each primer pair 
Primer SNP Approximate Optimum Ta (°C) 
KLF12 rs9600160 58 
ARNTL rs7107287 57 
BDNF rs6265 58 
ALDH1A1 rs1888202 57 
A2BP1(A) rs7204975 53 
A2BP1(B) rs10500336 53 
MBP rs12967023 57 
AK3L1 rs4916031 57 
GSK3β rs334558 62 
ANK3 rs9804190 57 
CACNA1C rs1006737 62 
 
 
3.4.2 PCR Conditions for Candidate Genes 
Based on optimum Ta and PCR product size, each of the amplicons was amplified in one 
of five multiplex reactions. The amplified products were then resolved on a 2% agarose 
gel (Appendix 3) and stained with EtBr. The first lane of each gel (Figures 8-12) 






















the negative (water) control. None of the water controls had amplified product indicating 
that none of the PCR reactions were contaminated.  
 
Group A consisted of three primer pairs, ARNTL rs7107287, MBP rs12967023, and 
ALDH1A1 rs1888202 and had a Ta of 57°C (See Figure 8). Primer dimers formed at the 
bottom of each lane. The GSK3β rs334558 and CACNA1C rs1006737 primer pairs 
constituted Group B and had amplicon sizes of 302bp and 220bp, respectively (Figure 
9). The Ta of this group was 62°C. Group C also consisted of two primer pairs, KLF12 
rs9600160 and BDNF rs6265. The Ta of this group was 58°C and had amplicon sizes of 
180bp (KLF12) and 338bp (BDNF) (Figure 10). Groups, D and E, each consisted of two 
primer pairs. Group D was made up of the two A2BPI primer pairs, A2BP1(A) rs7204975 
and A2BP1(B) rs10500336 (Figure 11). The amplicon sizes were 192bp and 250bp, 
respectively, and had a Ta of 53°C. The primer pairs AK3l1 rs4916031 and ANK3 
rs9804190 formed part of Group E which had a Ta of 57°C (Figure 12). These had 
amplicon sizes of 155bp and 227bp, respectively. The primer pairs of Group C and Group 
E were originally placed into one multiplex reaction (due to similar optimal Ta). 
However, when these products were resolved on a gel, it was noted that amplification of 
AK3L1 rs4916031 (155bp) was very faint and not easily distinguishable from the KLF12 
rs9600160 (180bp) fragment. Therefore, these four primer pairs were separated into 
















Figure 8: Group A PCR Products for three primer pairs- MBP rs12967023 (170bp), 
ARNTL rs7107287 (237bp), ALDH1A1 rs1888202 (394bp). Lane M: 100bp MWM. 












Figure 9: Group B PCR Products for two primer pairs- CACNA1C rs1006737 














































Figure 10: Group C PCR Products for two primer pairs- KLF12 rs9600160 (180bp), 












Figure 11: Group D PCR Products for two primer pairs- A2BP1(A) rs7204975 















































Figure 12: Group E PCR Products for two primer pairs- AK3L1 rs4916031 (155bp), 
ANK3 rs9804190 (227bp). Lane M: 100bp MWM. Lane C: water control. 
 
3.5 SNaPshot PCR 
3.5.1 Sap and ExoI Clean-up of PCR Products 
PCR products were purified with SAP and ExoI. To allow for further multiplexing, which 
in turn saved reagents and time, product from Groups A and B were multiplexed in the 
same clean-up reaction i.e. an equal ratio of Group A and Group B PCR products were 
pooled. Similarly, Groups C, D, and E PCR products were multiplexed in the same clean-
up reaction. 
3.5.2 Capillary Electrophoresis on ABI PRISM 
Due to multiplexing at the SAP and ExoI clean-up stage, genotyping was performed for 
two multiplexed reactions: Group A-B and Group C-D-E. Group A-B consisted of 
genotypes for five SNPs and Group C-D-E for six SNPs. Thus, the genotypes for 11 SNPs 
were incorporated into two SNaPshot reactions. SNaPshot reactions for Group A-B and 
Group C-D-E are represented by Figures 13 and 14, respectively. Homozygous 




























overlapping or adjacent peaks, of different colour. G-alleles are blue, C-alleles are black, 
T-alleles are red and A-alleles are green in colour.  
3.5.3 Analysis of Results 
 
Figure 13: SNaPshot results for Group A-B. Yellow pane- ARNTL rs7107287 
(genotype: GG), green pane- MBP rs12967023 (genotype: CT), red pane- ALDH1A1 
rs1888202 (genotype: GG), pink pane- GSK3β rs334558 (genotype: TT), purple 
pane- CACNA1C rs1006737 (genotype: GG). Y-axis represents fluorescent units. X-




Figure 14: SNaPshot results for Group C-D-E. Blue pane- ANK3 rs9804190 
(genotype: CC), purple pane- AK3L1 rs4916031 (genotype: AA), yellow pane- 
A2BP1(B) rs10500336 (genotype: TT), pink pane- KLF12 rs9600160 (genotype: 
AA), green pane- BDNF rs6265 (genotype: CC), orange pane – A2BP1(A) rs7204975 
(genotype CC). Y-axis represents fluorescent units. X-axis represents base position. 













3.6 Genotype Validation 
3.6.1 PCR of DNA Samples for Cycle Sequencing 
Figure 15 illustrates CACNA1C rs1006737 PCR products (Lanes 1-3) used for 
sequencing. The first lane of the gel contained the 100bp MWM (Appendix 3) and the 




Figure 15: PCR amplification for cycle sequencing reaction. Lane M: 100bp MWM. 
Lane C: water control. Lanes 1-3: CACNA1C rs1006737 (220bp) PCR product.  
 
 
3.6.2 Cycle Sequencing  
In total, 32 samples were sequenced for validation of SNaPshot genotyping. These 
samples represented the genotypes for each of the 11 SNPs (KLF12 rs9600160 had only 
two genotypes present in the sample population).   
3.6.3 Analysis of Results 
Sequencing results are represented by Figures 16 and 17. Figure 16 represents a 
portion of the sequencing results of the BDNF rs6265 SNP. This particular sample was 
homozygous C for this SNP, which is represented as a blue peak in the electropherogram 




















sample (C/T) for the SNP ANK3 rs9804190. This is seen by the blue and red peaks at 
position 142 (as indicated by the red arrow).  
 
 
Figure 16: Sequencing results for BDNF rs6265. This particular sample was 








Figure 17: Sequencing results for ANK3 rs9804190. This particular sample was 














3.7 Statistical Analysis for Case Control Association 
3.7.1 Genotype Frequencies, Hardy Weinberg Equilibrium Calculations and 
Logistic Regression with R 
Genotype counts of each SNP, for cases (n=224) and controls (n=202), are displayed in 
the following graphical outputs Figures 18 (A, B, C, D, E, and F) and 19 (A, B, C, D, and E). 
KLF12 (rs9600160) had no homozygous G individuals. It is evident from these figures, 
that there are no large differences in genotype frequencies between cases and controls. 
For control samples, none of the SNPs were found to be out of HWE. As a number of cases 
were related to one another, a random affected individual was selected for logistic 
regression analysis (logistic regression cannot adjust for relatedness). This resulted in a 
case cohort of 168 unrelated individuals. Based on the results from logistic regression, 
both gender (p-value 0.0151) and ethnicity (p-value 0.0107) had an association with 
disease affection status. Therefore, all subsequent association analyses were adjusted for 
gender and ethnicity. Case-control analysis showed that ANK3 rs9804190 and A2BP1 
rs7204975 were the only SNPs to have obtained a p-value of less than 0.05 (Table 17), 
in a recessive genetic model. This suggests that having two copies of the C-allele of the 
ANK3 rs9804190 increased the risk of being diagnosed with BPD by an odds ratio of 
1.68. Also, being homozygous for the C-allele of A2BP1 rs7204975, increased the risk of 
having BPD by an odds ratio of 1.77. Therefore, being homozygous C at both SNPs 
increases the risk for BPD nearly two fold. However, after adjusting for multiple testing 
using Bonferroni correction (new p-value cutoff 0.0038), these SNPs were no longer 














     
     





Figure 18: Genotype counts of cases and controls for the following SNPs A) ARNTL 
rs7107287, B) MBP rs12967023, C) ALDH1A1 rs1888202, D) GSK3β rs334558, E) 
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Figure 19: Genotype counts of cases and controls for the following SNPs of A) AK3L1 
rs4916031, B) KLF12 rs9600160, C) A2BP1(A) rs7204975, D) A2BP1(B) rs10500336, 
and E) BDNF rs6265. 














Table 17: R logistic regression output for case-control data using a recessive genetic 
model (adjusted for gender and ethnicity) 
Gene SNP Odds Ratio Lower Upper Z-test p-value 
ARNTL rs7107287 1.21 0.77 1.91 0.82 0.4139 
MBP rs12967023 0.89 0.55 1.45 -0.45 0.6516 
ALDH1A1 rs1888202 1.44 0.81 2.56 1.25 0.2131 
GSK3B rs334558 0.80 0.48 1.34 -0.85 0.3979 
CACNA1C rs1006737 1.19 0.57 2.51 0.47 0.6416 
ANK3 rs9804190 1.68 1.04 2.72 2.14 0.0324 
AK3L1 rs4916031 0.87 0.55 1.36 -0.61 0.5437 
A2BP1(B) rs10500336 0.97 0.31 3.02 -0.04 0.9642 
KLF12 rs9600160 1.17 0.65 2.10 0.51 0.6101 
BDNF rs6265 0.71 0.44 1.18 -1.31 0.1893 
A2BP1(A) rs7204975 1.77 1.09 2.89 2.30 0.0215 
 
 
3.7.2 MQLS  (adjusting for relatedness) and Pedstats 
MQLS is a software package capable of analyzing case-control data where certain individuals 
within the study are related to one another. For this analysis, genotypes needed to be 
represented in a pedigree file which specified familial relationships between individuals 
(including unaffected, non-genotyped family members). Before MQLS analysis could be 
performed, Pedstats a freely available program, was used to execute quality checks on 
pedigree data. For example, it was able to detect Mendelian inconsistencies whereby a 
mother was homozygous for one allele at a particular SNP and her offspring was 













the offspring would have to have inherited one of the alleles from the mother and either be 
homozygous for the “maternal” allele or be heterozygous at that position. This Mendelian 
inconsistency was due to genotype calling error and could therefore be rectified. Therefore, 
Pedstats was able to ensure that pedigree data based on genotypes were “error-free”. From 
the Pedstats results (Table 18), there were 593 individuals overall, in the pedigree file, 
with 370 families. There were 280 females and 258 males (the genders for a number of 
individuals were unknown).   
 
From the MQLS output (Table 19), it can be noted that only one of the SNPs, MBP 
rs12967023 obtained a significant p-value of less than 0.05. However, after Bonferroni 
correction for multiple testing, this SNP was no longer significant. It is noted that A2BP1(A) 
rs7204975 had a p-value approaching significance (p-value 0.0678).  
 
No significant interactions were found, between ANK3 rs9804190, A2BP1(A) rs7204975, 
and MBP rs12967023, after adjusting for Bonferroni Correction (results not shown).  
 
 
Table 18: Pedigree structure from Pedstats output 
No. of individuals in Pedigree File 593 
No. of Founders 385 
Gender Distribution 280 Females, 258 Males 
























ARNTL rs7107287 1.85983 0.403857 0.1726 
MBP rs12967023 4.84863 1.05287 0.0277 
ALDH1A1 rs1888202 0.075409 0.016375 0.7836 
GSK3β rs334558 0.24238 0.052632 0.6225 
CACNA1C rs1006737 0.242548 0.052669 0.6224 
ANK3 rs9804190 0.150696 0.032723 0.6979 
AK3L1 rs4916031 0.064394 0.013983 0.7997 
A2BP1(B) rs10500336 0.450299 0.097781 0.5022 
KLF12 rs9600160 0.014813 0.003217 0.9031 
BDNF rs6265 0.964785 0.2095 0.3260 
A2BP1(A) rs7204975 3.33621 0.724448 0.0678 
 
 
3.8 Statistical Analysis of Neuro-imaging 
The following imaging data (reported as cubic millimeters (mm)), were obtained for a small 
subset of affected individuals (n=22), of the larger cohort: right, left and total hippocampal 
volumes (HCV) and intracranial volumes (ICV). Each of the HCVs was divided by the ICV to 
account for inter-individual differences in brain volume. This accounted for differences in 
cranial volumes across gender and ethnicity. The Shapiro-Wilk test was used to determine 
whether imaging data were normally distributed. Results from this test indicated that only 
left HCV/ICV measure was not normally distributed (p-value 0.03). Therefore, the Kruskal-
Wallis rank sum test, the non-parametric equivalent to ANOVA, was used to determine 













groups. Bartlett’s test was used to ensure that all variances were equal amongst the 
genotype groups. All calculations indicated non-significant p-values (not shown), therefore, 
all groups had equal variances. Results from Table 20 (Kruskal Wallis chi-squared, F-values 
(ANOVA) and p-values) suggests that none of the genotypes have an association with left 
HCV/ICV, right HCV/ICV, and total HCV/ICV.  
 
Table 20: Kruskal Wallis and ANOVA values for each of the SNPs and imaging 





Left HCV/ICV Right HCV/ICV Total HCV/ICV 
KW chi-
squared 
p-value F-value p-value F-value p-value 
ARNTL rs7107287 1.0909 0.2963 0.996 0.3308 0.7478 0.398 
MBP rs12967023 2.4304 0.2967 1.6437 0.2210 1.3163 0.2927 
ALDH1A1 rs1888202 2.3211 0.3133 1.1948 0.33 1.3019 0.3011 
GSK3β rs334558 1.9813 0.3713 1.0793 0.3598 1.0866 0.3574 
CACNA1C rs1006737 4.7621 0.09246 1.9667 0.1674 1.806 0.1914 
ANK3 rs9804190 2.7391 0.2542 1.0134 0.3828 1.1203 0.3479 
AK3L1 rs4916031 2.6 0.2725 1.8067 0.1927 1.623 0.2249 
A2BP1(B) rs10500336 0.8475 0.6546 0.9849 0.3918 0.8857 0.4288 
KLF12 rs9600160 1.0435 0.307 2.3747 0.1390 1.5087 0.2336 
BDNF rs6265 1.1938 0.2746 1.5175 0.2323 1.2198 0.2825 













Chapter 4: Discussion 
 
BPD is a severe disorder affecting the lives of millions of individuals worldwide. 
Currently, the exact aetiology of BPD is unknown, treatment options are limited and a 
definitive cure seems distant. Due to the high heritability of this disorder, genetics is 
thought to be a key factor in the discovery of the pathophysiology. However, to date, 
even with high through-put genomic technologies, this has proven to be challenging. 
Numerous genes have been implicated in the aetiology of BPD, but have subsequently 
been difficult to replicate in independent studies. Besides genetic research, brain 
imaging has also been utilized in an attempt to elucidate biological mechanisms of BPD 
causality or association. However, as with genetic research, findings have been 
inconsistent. 
 
In the present study, ten genes were selected from a wide range of candidate genes 
which were prioritized through a convergent approach and GWAS. It was found that 
SNPs in the genes ANK3, A2BP1 and MBP may play a role in the aetiology of BPD. In 
addition, due to the e abling multidisciplinary research environment here at UCT, it 
was possible to explore a dimension of brain imaging research of BPD subjects for 
whom genetic studies were also undertaken. In this pilot study of 22 affected 
individuals, none of the SNPs in ten genes tested were associated with MRI features.  
 
Over the years, in efforts to determine the underlying genetics of BPD, linkage, 
association, and GWAS have implicated numerous chromosomal regions and genes. 













could be due, at least in part, to aetiological heterogeneity [Faraone and Tsuang, 2003]. 
The Division of Human Genetics at UCT has a well characterized BPD archive which 
serves as a rich resource for genetic studies of the disorder. This cohort is 
predominantly familial (total of 221 families), and limited to a few ethnic groups, which 
is surmised to reduce the aetiological heterogeneity. The offspring of individuals 
affected with BPD are at higher genetic risk for developing the disorder and offer a 
significant source of convergent information regarding the development of this 
disorder. Gene-environment interactions may also be assessed in this circumstance as 
these offspring may have been affected by mood episodes experienced by the affected 
parent [Chang et al., 2003]. Another way of attempting to reduce genetic and 
aetiological heterogeneity i.e. to have a more homogeneous study group, is to sample 
geographically and genetically isolated populations. These derived cohorts may be 
advantageous as they may have a higher prevalence of certain diseases, an 
endogamously-related probability of mapping recessive genes, and less migration 
[Peltonen et al., 2000]. In our cohort, the Afrikaner Caucasians and indigenous African 
Xhosa-speaking populations are relatively homogenous and genetically isolated, and 
may be ideal candidates for psychiatric genetic research. However, due to the small 
numbers of indigenous Africans and other isolated ethnic groups in our cohort, 
individuals from this population group were not included in the current study.   
 
The first aim of this investigation was to determine whether variants in ten selected and 
previously associated candidate genes are risk factors for the development of BPD. 
Logistic regression is a statistical method commonly used in the analysis of case-control 
data. Using this statistical method, and indicating a recessive genetic model, only ANK3 













associations with BPD. Thus, individuals who were homozygous C at both SNPs had an 
increased risk for BPD. This suggests that BPD is a recessive disorder whereby 
individuals require two copies of the disease-predisposing allele to be affected. 
However, the mode of inheritance of BPD is thought to be non-Mendelian and a result of 
the interaction of numerous genes with the environment [Serretti and Mandelli, 2008]. 
After adjusting for multiple testing using the Bonferroni correction method, none of the 
SNPs were statistically significant. This situation may reflect i) that there are no genuine 
associations, or ii) that there is some association and this disappears upon correction 
for multiple testing. The Bonferroni correction decreases Type I error (the probability 
of rejecting the null hypothesis, when it is true). This method is often used as it is 
relatively simple to calculate and can be applied to most multiple-testing scenarios 
[Bender and Lange, 2001]. However, the Bonferroni correction has often been criticized 
as being overly conservative and increases the chances of Type II error (the probability 
of rejecting the alternate hypothesis, when it is true) [Perneger, 1998]. Thus, the debate 
continues as to whether correction for multiple-testing, particularly using the 
Bonferroni method, is necessary for genetic studies. In light of this, it is worth re-
examining the biological role of the two candidates: ANK3 and A2BP1. 
 
ANK3 encodes a neurally expressed, structural protein that is thought to be involved in 
the maintenance of ion channels and cell adhesion molecules of axonal segments 
[Kordeli et al., 1995]. Four GWAS, in various population groups, have shown ANK3 
associated with BPD [Baum et al., 2008; Ferreira et al., 2008; Scott et al., 2009; Smith et 
al., 2009]. These findings were replicated in a meta-analysis study consisting of 
Caucasian subjects (n=1668 cases and 1604 controls) [Schulze et al., 2008]. The 













functional significance. ANK3 is located on chromosome 10, in a region that was 
originally linked with late onset Alzheimer’s disease [Myers et al., 2000]. Subsequently, 
a candidate gene association study detected a nominal association of this gene and late 
onset Alzheimer’s disease [Morgan et al., 2008].  
 
A2BP1 encodes a RNA-binding protein, which interacts with the gene ataxin-2 which has 
been shown to underlie the aetiology of the neurodegenerative disorder, SCA type 2 
[Shibata et al., 2000; Kiehl et al., 2001]. This gene was previously found to be associated 
with several neuropsychiatric disorders, including attention deficit hyperactivity 
disorder (ADHD) [Elia et al., 2009], autism [Martin et al., 2007], and Schizoaffective 
Disorder [Hamshere et al., 2009]. The A2BP1 SNP, rs7204975, is located within an 
intron of the gene, and seemingly, has no known functional significance. However, it 
may be in linkage disequilibrium with the causal variant or it may play a role in the 
regulation of the gene. This SNP was found to be associated with BPD, in a German 
population group, by a previous GWAS (p-value 0.001) [Baum et al., 2008]. However, 
A2BP1(B) rs10500336 which had a p-value of 0.018 in the same GWAS, did not attain 
significance in the current study. 
 
From the MQLS analysis, only MBP rs12967023 showed a nominal association with a p-
value of less than 0.05. However, after correction for multiple testing, this finding was 
no longer significant. The product encoded by MBP comprises 30% of the protein in CNS 
myelin. Myelin is found around the axons of neurons and increases the velocity of nerve 
impulses [Kamholz et al., 1987]. MBP expression has been shown to be reduced in SCZ 
postmortem brains [Tkachev et al., 2003] and a decreased intensity of myelin staining 













study has shown that an affected twin (n=24) has significantly reduced white matter 
volumes compared to the unaffected co-twin (n=15) and demographically matched 
control twins (n=27) [Kieseppä et al., 2003]. MBP has also been implicated in the 
recovery from neuronal insults. In animal models, autoimmune T-cells, activated against 
the CNS antigen MBP, reduce degeneration after optic nerve injury [Hauben et al., 
2000]. Furthermore rats that have been immunized with MBP show more severe 
neuronal loss after CNS injury [Jones et al., 2004]. This suggests that MBP has a possible 
role in the progression of neurodegeneration. The MBP SNP, rs12967023, is located 
within an intron, therefore, the exact function is unknown. This SNP has however been 
previously associated with BPD (p-value 0.001) in a GWAS involving Caucasian subjects 
[Sklar et al., 2008].  
 
Surprisingly, none of the other candidate genes (or at least the SNPs assayed) was found 
to be associated with BPD. BDNF, and particularly the Val66Met polymorphism, has 
often been found to be associated with BPD [Neves-Pereira et al., 2002; Sklar et al., 
2002; Lohoff et al., 2005; Muller and De, 2006; Okada et al., 2006]. However, the results 
of the current study are in accordance with many studies that have not found an 
association between BPD and this neurotrophic factor [Nakata et al., 2003; Kunugi et al., 
2004]. CACNA1C which has been strongly associated with BPD in a GWAS [Ferreira et 
al., 2008] and replicated in independent studies [Scott et al., 2009; Schulze et al., 2008] 
was not associated with BPD in the present study. The difference in results between the 
current and previous studies could be due to any one, or a combination, of several 
factors including the different ethnic groups under investigation, differences in study 














The final cohort consisted of 224 subjects affected with BPDI and 202 background 
control individuals. The controls formed part of the background population and were 
not screened for any psychiatric illness. Thus, in accordance with the estimated 
prevalence of BPD, 1% of these controls may have been predisposed to BPD. The cases 
and controls were not “matched” with respect to gender and ethnicity. However, it is 
acceptable to adjust for potential confounders such as gender and ethnicity in the 
regression analysis [Bland and Altman, 1994].   
 
An association was found between gender and BPD. This is not in accordance with 
previous findings, where it has been shown that BPD affects both males and females at 
equal frequencies [Merikangas et al., 2007; American Psychiatric Association. Task 
Force on DSM-IV, 1994]. However, it has been found that men, generally, have an earlier 
age of onset than females [Kennedy et al., 2005]. In the current study, differences in 
genotype frequencies between Caucasian and Mixed Ancestry individuals were 
observed. This finding does not agree with a previous U.S. study which found no 
difference in BPD prevalence amongst ethnic groups (n=9282 study subjects) 
[Merikangas et al., 2007]. However, different ethnic groups (viz. Hispanic, Caucasian, 
and African American) were investigated by Merikangas et al. [2007], compared to the 
current study which included Caucasians (British and Afrikaner ancestry) and 
individuals of Mixed Ancestry. The South African Mixed Ancestry group is an admixed 
population group consisting of individuals of Khoesan, Bantu-speaking African, 
European and Asian ethnicity [de Wit et al., 2010].   
 
The second aim of the current study was to determine whether the endophenotypic 













component of the project should be considered a pilot study as there were only 22 
participants with both imaging and genotyping data available. Nonetheless, previous 
imaging genetic studies have had similar sample sizes [Bueller et al., 2006; Chepenik et 
al., 2008]. As with other similar studies, the brain area under investigation was the 
hippocampus, involved in long-term memory [Squire, 1992], stress responses [Sapolsky 
et al., 1984] and spatial navigation [Maguire et al., 2000]. In this study, no association 
was found between any of the genotypes and hippocampal volumes (left, right and 
total), corrected for total intracranial volumes. This finding could be expected, as the 
study was a pilot, testing the technologies and analytical capacities between the clinical 
phenotype, imaging endophenotypes and genetic data. From the outset, it was obvious 
that the small sample size and potential number of tests would render the study 
inadequately powered. 
 
Previous studies have implicated the BDNF rs6265 (Val66Met) polymorphism with 
hippocampal volume. In healthy controls, the Met-allele was associated with reduced 
hippocampal volumes [Bueller et al., 2006; Chepenik et al., 2008]. These findings have 
also been shown for ind viduals affected with major depression (n=60 cases and 60 
controls) [Frodl et al., 2007]. However, results from the current study suggest that there 
is no association between BDNF rs6265 and brain hippocampal and intracranial 
volumes of individuals affected with BPDI. This finding is similar to that shown by Dutt 
et al. [2009] where the BDNF rs6265 SNP has no association with hippocampal volumes 















4.1 Future Directions 
Future studies should consider the following aspects: The functionality of the following 
SNPs should be investigated: ANK3 rs9804190, A2BP1 rs7204975 and MBP 
rs12967023. Statistical significance of genotype with diagnosis does not illustrate the 
biological mechanism for risk. Therefore, the underlying biology needs to be 
determined [Bigos et al., 2010]. The effect of the SNPs on expression of the gene can be 
investigated by the use of Allelic Expression Imbalance (AEI). This method relies on the 
differentiation of maternal and paternal alleles and to determine the relative mRNA 
expression of each [Buckland, 2006]. An individual needs to be heterozygous at the SNP 
of interest and any deviation from a 50:50 expression of each allele suggests an effect of 
the genetic variation [Quinn et al., 2010].   
 
It is possible that other variants, within the candidate genes investigated, have an 
association with BPD. High throughput technologies, such as next generation re-
sequencing, could be used to get a more dense coverage of variants, in a wide range of 
subjects, of a particular candidate gene. For example, exome sequencing has been able 
to identify the candidate gene and variants underlying the aetiology of a rare Mendelian 
disorder [Ng et al., 2009]. 
 
Subsequent to their original CFG publication, Le-Niculescu et al. [2008] did a follow-up 
study whereby they re-generated a prioritized BPD list using four instead of three 
GWAS results and included other, more recent lines of evidence [Patel et al., 2010]. The 
top three candidate genes were the same as those from the 2008 study. They also 
developed a genetic risk prediction score (GRPS) whereby individuals affected with BPD 













of SNPs from the CFG list (which included the MBP rs12967023 SNP), providing proof of 
principle whereby the candidate gene list could be used to predict risk for developing 
BPD at a population level [Patel et al., 2010]. Although it may not be used clinically yet, 
this predictive value is enormously important in dismantling large heterogeneous 
cohorts into more aetiologically homogeneous entities, towards identifying the 
underlying range of molecular pathologies. 
  
Future work could also investigate alternate candidate genes. Interestingly, genes that 
have been previously implicated in the aetiology of cancer have also been shown to be 
significant for BPD. The WTCCC GWAS found a significant signal for the locus containing 
the PALB2 gene [Stratton, 2007]. This finding was replicated in a subsequent study 
whereby both PALB2 and breast cancer 2 (BRCA2) were found to be positively 
associated to BPD in a Scandinavian population group [Tesli et al., 2010].  
 
Recently, work done by our group on a subset of the larger BPD cohort, have shown that 
genes involved in glutamatergic signaling have an association with BPD severity. The 
gene for glutamate receptor, metabotropic 3 (GRM3) was associated with a four-fold 
increased risk of having psychotic symptoms and the genes, ionotropic glutamate 
receptor, N-methyl D-aspartate 2B (GRIN2B) and D-amino acid oxidase activator (DAOA) 
interact to increase the risk of being admitted to hospital for mania [Dalvie et al., 2010] 
(Appendix 8). Therefore, these genes and others involved in glutamatergic signaling, 















With regard to the imaging genetics, it is obvious that the technologies are at hand to 
carry out the work in this promising area. Apart from a significant increase in numbers 
of subjects, imaging data should be obtained from control individuals to determine 
whether hippocampal volumes have an association with BPD. Changes in hippocampal 
volumes have often been described in psychiatric illnesses such as borderline PD, PTSD, 
major depressive disorder (MDD) [Bremner et al., 2000] and BPD. Chepenik et al. 
[2009] have found that BPD-affected individuals have smaller hippocampal volumes 
compared to controls. However, results have varied across studies. Some studies have 
not found differences in hippocampal volumes between individuals affected with BPD 
and controls [Hajek et al., 2009].  
 
Since the implicated candidate genes (i.e. ANK3, A2BP1 and MBP) have been shown to 
have a relationship with neurodegeneration, it would be of interest to determine 
whether any of these genes have an association with any neurodegenerative disorders. 
The Division of Human Genetics has a long history of investigating neurodegenerative 
disorders such as SCA [Bryer et al., 2003; Greenberg et al., 2006] and Huntington’s 
Disease [Greenberg et al., 1991; Squitieri et al., 1994; Bardien et al., 2007; Scholefield 
and Greenberg, 2007]. A cursory study may involve investigating neurodegenerative 
symptoms or disorders in individuals or families where the BPD phenotype is 
associated with these genes.   
4.2 Conclusions 
This study showed that intronic SNPs within ANK3, A2BP1 and MBP may have an 
association with BPD and that polymorphisms within the ten investigated candidate 
genes do not show an association with endophenotypic measures of BPD. The three 













disorders [Hauben et al., 2000; Myers et al, 2000; Shibata et al., 2000; Kiehl et al., 2001; 
Jones et al., 2004; Morgan et al., 2008]. Neurodegenerative disorders such as 
Parkinson’s and Huntington’s are characterized by a loss of neurons, BPD has often 
been shown to be accompanied by a decrease in neuronal plasticity as well as decreases 
in various regional volumes [Rajkowska, 2002]. This disorder has also been shown to be 
associated with minor cognitive impairments [Martinez-Aran et al., 2004], as well as an 
increased risk for developing dementia in the elderly [Nunes et al., 2007]. This may 
suggest that BPD could be considered to have features in common with the classical 
neurodegenerative disorders. Therefore, it can be postulated that the pathophysiology 
of BPD has a link with neurodegeneration. 
 
The present study highlights the importance of examining complex phenotypes in a 
familial setting where the traditional view of comorbidities may be examined across 
individuals “at risk”. Phenotypic studies in such high risk subjects and families continue 
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REQUEST FOR MOLECULAR STUDIES (DNA) 
 
Molecular Laboratory  
Division of Human Genetics Blood should be drawn in 2 plastic EDTA Tubes 
IIDMM, LEVEL 3 (Purple top) +/- 10ml each using a yellow barrel. 
UCT Medical School, Observatory 7925 Each tube should be inverted to mix and should be  
 clearly labelled with the patient's name and DOB 
Tel: (021) 406 6425        Fax: (021) 406 6826 Keep blood in fridge at 4°C until able to send to laboratory 
  
 Please DO NOT send specimens on ice or frozen. 




New Family:  Yes    No    (If no, please fill in family name)  Family name: ________________________________________ 
 
Medical Aid: ________________________________________________Medical Aid No: ________________________________ 
 
Sex:     M        F    Date of Birth:  Year:_____________  Month:_____________________  Day: ______________________ 
 
Number  of children: ______________________________________ 
 
Ethnic Origin : ( please indicate ancestry of both your mother and father )_______________________________________________ 
        Fax: 
Contact Address:  ____________________________________ Town: _______________________ Tel: ___________________ 
 
        Fax: 
Referring Doctor/Sister: ______________________________ Town:  ______________________ Tel: ___________________ 
 
        Fax: 
Hospital or Address:  _________________________________ Town:  ______________________ Tel: ___________________ 
 
 
Reason for Referral  (Clinical diagnosis): 
 
Affected                At Risk                 Carrier                 Spouse                 Query                 Unaffected   
 
Becker Muscular Dys.  Duchenne Muscular Dys   Colonic Carcinoma   
Fragile-X Syndrome   Bipolar Disorder  Huntington Disease  
Retinitis Pigmentosa   Spinocerebellar Ataxia   Waardenberg Syndrome   
 
Additional disorders (apparent or previously treated):  ______________________________________________________________ 
 




Physical disability           Mental retardation             Deafness             Impaired vision            Night blindness       
 
Other:  _________________________________________________________________________________________________ 
 
Have samples from this patient been sent to a DNA lab before? (DELETE WHERE NOT APPLICABLE)  YES / NO / Don't Know 
 
If Yes, where: ___________________________________________________________________________________________ 
 
For Laboratory use only: 
 
DNA number: _____________________________________  Vol.Blood: ________________(ml)     Other: _________________ 
 
Date Received:   Year: ________  Month:  ____________  Day:  _____________        Computer Index No:__________________ 
 
 




I, ____________________________________________________________________  , request that an attempt 
be made using genetic material to assess the probability that:  I /  my child  /  my  unborn child  (DELETE 
WHERE NOT APPLICABLE) might have inherited a disease-causing mutation in the gene 
for:______________________________________________________________________________________ 
  
2. I understand that the genetic material for analysis is to be obtained from:  blood cells/skin sample/other (specify) 
(DELETE WHERE NOT APPLICABLE) :     
  
3. I request that no portion of the sample be stored for later use.   (MARK IF APPLICABLE ) 
  Or 
I request that a portion of the sample be stored indefinitely for (DELETE WHERE NOT APPLICABLE): 
 ( a )  possible re-analysis 
 ( b )  analysis for the benefit of members of my immediate family 
 ( c )  research purposes,  subject to the approval of the University of Cape Town Research Ethics 
         Committee, provided that any information from such research will remain confidential. 
  
4. The results of the analysis carried out on this sample of stored biological material will be made known to me,  
via my doctor, in accordance with the relevant protocol,  if and when  available.  
In addition, I authorise that they may be made known to:  (DELETE WHERE NOT APPLICABLE) : 
 other doctors involved in my care 
 the following family members:   ___________________________________________________________ 
 other: _______________________________________________________________________________ 
  
5. I authorise / do not authorise my doctor(s) (DELETE WHERE NOT APPLICABLE) to provide relevant clinical 
details to the Division of Human Genetics, UCT. 
  
6. I have been informed that:  
( a ) there are risks and benefits associated with genetic analysis and storage of biological material and 
these have been explained to me.  
( b ) the analysis procedure is specific to the genetic condition mentioned above and cannot determine 
the complete genetic makeup of an individual. 
( c ) the genetics laboratory is under an obligation to respect medical confidentiality . 
( d ) genetic analysis may not be informative for some families or family members. 
( e ) even under the best conditions, current technology of this type is not perfect and could lead to 
incorrect results. 
( f ) where biological material is used for research purposes, there may be no direct benefit to me. 
  
7. I understand that I may withdraw my consent for any aspect of the above at any time without this affecting my 
future medical care. 
  
8. ALL OF THE ABOVE HAS BEEN EXPLAINED TO ME IN A LANGUAGE THAT I UNDERSTAND 
AND MY QUESTIONS ANSWERED BY: 
  









NOTE - PLEASE INSERT A FAMILY PEDIGREE DRAWING ON THE REVERSE OF THIS FORM 
 














Appendix 2: Gentra PuregeneTM DNA Isolation Protocol 
 
 Added 900µl red blood cell lysis solution to microcentrifuge tube 
 
 Added 500µl whole blood and mixed by inverting 
 
 Incubated for one minute at room temperature 
 Centrifuged for 20 seconds at 13 000rpm to pellet white blood cells. Discarded 
supernatant 
 Added 300µl cell lysis solution and vortexed 
 Incubated at 37°C for ten minutes 
 Added 100µl protein precipitation solution and inverted 
 Centrifuged for one minute at 13 000rpm 
 Added supernatant to clean microcentrifuge tube with 300µl isopropanol 
 Mixed by inversion until DNA was visible as threads or clumps 
 Centrifuged for one minute at 13 000rpm 
 Discarded supernatant 
 Added 300µl 70% ethanol and inverted several times 
 Centrifuged for one minute 13 000rpm 
 Discarded supernatant 





















Appendix 3: Reagents, Buffers and Solutions 
 
Molecular weight marker- GeneRuler™ 100 bp Plus DNA Ladder (Fermentas Life 
Sciences, Hanover, USA)  
 
 25µl stock 100bp DNA ladder solution 
 225µl dH2O 







10x TBE Buffer (stock) 
 216g (0.89M) Tris (B&M Scientific cc, Cape Town, SA) 
 110g (0.89M) Boric Acid (MP Biomedicals Inc., USA) 
 14.8g (0.04M) EDTA (BDH Electron® Laboratory Supplies, UK) 















1x TBE Buffer (working stock) 








1% Agarose Gel (100ml)  
 1g agarose (Whitehead Scientific, SA) 
 100ml 1X TBE (working stock) 




2% Agarose gel (100ml)  
 2g agarose (Whitehead Scientific, SA) 
 100ml 1X TBE (working stock) 











































































Appendix 5: Ethanol Precipitation 
 
 The sequencing reaction was transferred to a 1.5ml eppendorf tube 
 Added 50µl absolute ethanol and 2µl sodium acetate (3mM, pH5.5) 
 Solution was mixed and left at -20 ºC for more than 1 hour 
 Spun @ 10 000rpm for 10 minutes 
 Supernatant was discarded 
 Added 50µl of 70% ethanol, vortexed 
 Spun @ 10 000rpm for 10 minutes 
 Supernatant was discarded 
 Air dried for approximately 1 hour to evaporate the ethanol 






























Appendix 6: Annealing Temperatures (Ta) for Temperature Gradient Reactions  
 































































ARNTL (237bp) Temperature Gradient. Lane M: Molecular Weight Marker (MWM). Lanes 1-12: 







BDNF (338bp)Temperature Gradient. Lane M: Molecular Weight Marker (MWM). Lanes 1-12: 



































ALDH1A1 (394bp) Temperature Gradient. Lane M: Molecular Weight Marker (MWM). Lanes 1-






A2BP1(A) (192bp) Temperature Gradient. Lane M: Molecular Weight Marker (MWM). Lanes 1-





A2BP1(B) (250bp) Temperature Gradient. Lane M: Molecular Weight Marker (MWM). Lanes 1-









































MBP (170bp) Temperature Gradient. Lane M: Molecular Weight Marker (MWM). Lanes 1-12: 






AK3L1 (155bp) Temperature Gradient. Lane M: Molecular Weight Marker (MWM). Lanes 1-12: 







































GSK3β (302bp) Temperature Gradient. Lane M: Molecular Weight Marker (MWM). Lanes 1-12: 





ANK3 (227bp) Temperature Gradient. Lane M: Molecular Weight Marker (MWM). Lanes 1-12: 
PCR products amplified at varying annealing temperatures as specified in Table 1.  Lane C: 





CACNA1C (220bp) Temperature Gradient. Lane M: Molecular Weight Marker (MWM). Lanes 1-
12: PCR products amplified at varying annealing temperatures as specified in Table 1.  Lane C: 











































Appendix 8: Psychosis and relapse in bipolar disorder are related to GRM3, 
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Introduction
The lifetime prevalence of bipolar disorder Type 1 (BD) is
approximately 1% in the US and Europe, and likely equally high
in Southern Africa.1,2 BD is associated with a high level of
mortality (between 10-20% of individuals affected with BD
successfully commit suicide) and morbidity (BD is estimated as
one of the top ten causes of disability worldwide).3-5 An earlier
age of disease onset, increased number of episodes and
hospitalisations for mania and depression, and the presence of
psychotic symptoms are markers of a more severe disease
phenotype.6-8 Previous research has not examined associations
between phenotype severity and glutamate signalling in BD,
although variants within brain derived neurotrophic factor
(BDNF) may be associated with indices of severity in BD.9-11
Glutamate signalling is involved in brain development and
synaptic plasticity, both of which are modified in individuals
affected with BD, and have been implicated in its aetiology.12,13
A range of psychotropics involved in the treatment of BD alter
glutamatergic function; for example, lamotrigine inhibits the
release of glutamate and lithium affects glutamate receptor
function.14 It has also been observed that variation in the
glutamate receptor encoding gene, GRIK4 (rs1954787) makes
subjects with depressive episodes more likely to respond to
citalopram.15 Fallin et al. found that the glutamatergic genes
most likely to be associated with BD rather than schizophrenia
(SZ) were GRM3 and GRIN2B, and replicated previous findings
of strong associations between DAOA and BD diagnosis.16
Glutamate receptor, metabotropic 3 (GRM3) encodes
subunit 3 of the Group II metabotropic glutamate receptors
Psychosis and relapse in bipolar
disorder are related to GRM3,
DAOA, and GRIN2B genotype
S Dalvie1, N Horn2, C Nossek1, L van der Merwe3,4, DJ Stein2, R Ramesar1
1Division of Human Genetics, MRC/UCT Human Genetics Research Unit, Faculty of Health Sciences, University of Cape Town Medical
School, Observatory, Cape Town, South Africa 
2Department of Psychiatry and Mental Health, University of Cape Town Medical School, Observatory, Cape Town, South Africa
3Biostatistics Unit, Medical Research Council, Cape Town, South Africa
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Abstract
Objective: Dysfunction in glutamate signalling is thought to play a role in the pathophysiology of bipolar disorder (BD). There is
evidence of associations between single nucleotide polymorphisms (SNPs) in GRM3, GRIN2B, and DAOA genes and the diagnosis
of BD. In this pilot study, we investigated the frequency of SNP variants in these 3 genes within South African population groups,
and assessed interactions between genes and phenotypes of BD disease severity. Method: Multiplex SNaPshotTM PCR was used
to genotype 191 case and 188 control samples. Cases comprised of 191 individuals in a South African cohort of mixed ancestry
and Caucasians, with BD Type 1. Phenotypes of BD disease severity were: age of onset, number of illness episodes, number of
hospitalisations for depression or mania and history of psychotic symptoms. Results: There were no significant difference in SNP
allele frequencies between cases and controls. In the case-only analysis, the GRM3 rs6465084 heterozygote was associated with
a 4-fold increased risk of lifetime history of psychotic symptoms, and the specific variants within the gene pair, DAOA and GRIN2B,
had a significant interaction with the number of hospitalisations for mania, with lowest admission rates associated with both pairs
of ancestral alleles. Conclusion: In BD, variations in glutamatergic genes may influence phenotypes related to the severity of
illness. Speculatively, newly derived genes associated with various evolutionary advantages, may also increase the risk for more
severe BD. These preliminary findings deserve validation in a larger cohort.
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(mGluR). In glutamate receptor, metabotropic 2 (GRM2) and
GRM3 knockout mice, Lyon et al. showed a compensatory up-
regulation of remaining group II mGluRs and the N-methyl
D-aspartate (NMDA) receptor subunit 2A (NR2A) expression,
and down-regulation of glutamate transporter expression.17
Post-mortem studies have suggest altered GRM3 expression in
BD.18 Crespi et al. identified GRM3 as one of 14 genes with
significant evidence of selection in human populations.19 GRM3
modulates glutamate neurotransmission by regulating the
excitatory amino acid transporter 2 (EEAT2). Egan et al. have
demonstrated that decreased levels of EEAT2 are associated
with a GRM3 SNP (rs6465084), which has a weak association
with SZ.20 Egan et al. have also demonstrated that individuals
who are homozygous A for GRM3 rs6465084 have lower levels
of N-acetylaspartate, an indirect indicator of synaptic function
and glutamate levels and suggests that GRM3 rs6465084 has an
effect on GRM3 transcript expression.20
Ionotropic glutamate receptor, N-methyl D-aspartate 2B
(GRIN2B) encodes the NR2B subunit of the NMDA receptor.
Mice with enhanced NR2B function show supernormal learning
and memory function, while BD sufferers consistently show
impairment in working memory.21 Associations have been
observed between several polymorphisms in the GRIN2B gene
and the 12p13.1-p12.3 region (containing the GRIN2B gene)
and BD.16,22,23 Miyatake et al. have observed that the T allele of
the GRIN2B rs1019385 SNP results in increased luciferase
transporter activity in the presence of nerve growth factor
(NGF).24 The presence of a G allele had no effect on reporter
activity, suggesting that GRIN2B rs1019385 may have a role in
transcriptional control of the GRIN2B transcript.24
The G72 gene product, D-amino-acid oxidase activator
(DAOA), activates the peroxisomal protein D-amino-acid
oxidase (DAO).25 This protein (G30) degrades D-serine, which
acts, similar to glycine, as a coactivator on the “glycine binding
site” of the glutamatergic NMDA receptor. Hashimoto et al.
showed that the percentage of D-serine in the total serine in the
cerebrospinal fluid of drug naïve SZ patients was significantly
lower than that of control samples.26 Genetic variants of
G72/G30 have been found to be associated with BD and
SZ.16,27-32 In some populations, the at-risk haplotypes are shared
between SZ and BD.31 The pathogenic mutations have not yet
been identified but might be located in the vicinity of the
G72/G30 gene complex or in the regulatory region.30
Method
Subjects
The cohort comprised of two groups: a group of BD Type 1
affected individuals (cases) and the background population
group (controls). Blood samples were previously obtained, with
the appropriate written informed consent. This study was
approved by the University of Cape Town Health Science
Faculty Research Ethics Committee (081/96) and is in
accordance with the guidelines of the Helsinki Declaration of
2000.
The Division of Human Genetics has a BD database
consisting of 883 individuals comprising 185 families. For the
purposes of this study, the cases consisted of 191 individuals
specifically diagnosed with BD Type 1 with the Structured
Clinical Interview for the DSM-IV (SCID). This group
comprised of 87 (46%) males and 104 (54%) females of ages
ranging from 22 to 91 years. Subjects included 103 (54%)
individuals of mixed ancestry and 88 (46%) Caucasian
individuals. The cases included 95 individuals from 36 families
that were related to at least one other case. The age of onset,
number of depressive episodes, number of hospitalisations
due to mania and depression of each of the cases were noted,
as well as history of psychotic symptoms. The control group
consisted of 188 unrelated individuals not diagnosed with any
psychiatric disorder, and similar to the cases in terms of age,
gender and ethnicity.
DNA Analysis
The following SNPs were chosen for genotyping based on
previous association to either BD or SZ: GRM3 rs6465084
(intronic), GRIN2B rs1019385 (5’ upstream), and DAOA
rs701567 (intronic).1-4 Gene sequences were obtained from the
National Center for Biotechnology Information (NCBI)
(http://www.ncbi.nlm.nih.gov) and Ensembl
(http://www.ensembl.org/index.html) databases and the SNP
locations were determined. DNA concentration and integrity
was determined by spectrophotometric quantification and
agarose gel electrophoresis, respectively. Polymerase chain
reaction (PCR) was performed on genomic DNA, according to
standard procedures, for each of the SNPs in the candidate
genes. The polymorphisms were genotyped using the
SNaPshot™ multiplex ready reaction mix (Applied Biosystems,
Warrington, UK) and the ABI Prism 3100 Genetic Analyzer
(Applied Biosystems, CA, USA). Genotyping results were
validated by cycle sequencing using BigDye Terminator Mix
(Applied Biosystems, CA, USA) and the ABI Prism 3100 Genetic
Analyzer (Applied Biosystems, CA, USA). 
Statistical Analysis
For the case-control analysis, one individual from each family
was randomly selected, leaving 132 unrelated cases. For this
analysis, logistic regression was used. 
The case-only analyses involved all 191 cases, which were
adjusted for relatedness. We used generalised linear models
for all the association tests. For age of onset, we used a normal
family with an identity link; for each of the three outcomes: (i)
number of depressive episodes, (ii) hospitalisations due to
mania and (iii) hospitalisations due to depression, we used the
Poisson family with a log link and for dichotomous history of
psychosis, a binomial family with logit link. There were only 4
GRM3 rs6465084 homozygous G cases. We therefore grouped
them with the heterozygotes for the case-only analyses.
Genotypes were coded as categories for the single-SNP
analyses, and numerical (number of minor alleles) for testing
interactions. 
All of the six outcomes analysed (case-control, age of onset,
number of depressive episodes, hospitalisations due to mania,
hospitalisations due to depression, and history of psychotic
events), were tested for an interaction between the three SNPs.
When this was not significant, we tested all pairwise
interactions between SNPs and where those were not
significant, we tested the individual SNPs (main effects). All
analyses were adjusted for gender, ethnicity and duration of
disease as fixed effects and family-membership as random
effect.
Statistical analyses were done with R, a language and
environment for statistical computing and graphics, and R
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Results
Case-control analysis (132 cases; 188 controls)
The differences in the genotype and allele frequencies
between cases and controls were not significant. Neither were
any SNP-interactions on case-control status significant (results
not shown). The allele frequencies for each of the SNPs
obtained from the cases and controls in the current study, are
displayed in Table I.
Case-only analysis (n=191)
All the results presented here were adjusted for gender, ethnic
group, duration of disease and family-membership.
We did not find any significant association between the
SNPs GRM3 rs6465084, GRIN2B rs1019385, DAOA rs701567
and main effects or interactions on age of onset (n=124),
number of depressive episodes (n=130), or number of
hospitalisations for depression (n=171). However, a significant
association between GRM3 rs6465084 and history of
psychosis (63% with a history and 37% without history of
psychosis) was found. The GRM3 rs6465084 G-allele was
found to increase the odds of having had a psychotic episode
(OR=3.9; p=0.004) considerably. Even after adjusting for
family-relatedness only, a significant association (OR=2.2;
p=0.0137) was observed. 
Reported number of hospitalisations for mania (n=167)
varied between 0 and 11. The interaction between DAOA
rs701567and GRIN2B rs1019385 on number of hospitalisations
for mania was significant (p=0.0108), and this interaction was
independently significant after including other interactions in
the model. The nature of the modelled interaction is illustrated
in Figure 1 and can be described as follows: For individuals
with the GRIN2B rs1019385 genotype G/G, their expected
number of hospitalisations for mania increased with their
number of DAOA rs701567 G alleles. For individuals with the
GRIN2B rs1019385 genotype G/T, there were smaller
decreases in number of hospitalizations and for those
individuals with the T/T genotype, each DAOA rs701567 G
allele resulted in larger decreases. Individuals who are
homozygous A for DAOA rs701567 and homozygous T for
GRIN2B rs1019385 had the largest number of hospitalisations,
and those who are homozygous G for DAOA rs701567 in
combination with being homozygous G for GRIN2B rs1019385,
had the second largest. Those with DAOA rs701567 G/G and
GRIN2B rs1019385 T/T had the least number of hospitalisations. 
Discussion
The first set of findings related to SNP frequency showed that
all 3 SNPs examined had a similar distribution between
Caucasian and mixed ancestry groups, and that BD diagnosis
was not associated with any of the SNPs examined. The
second set of findings, related to BD severity, was that the non-
ancestral GRM3 G allele at rs6465084 carries a 4 times
greater risk of developing psychosis in BD subjects, and that
alleles at DAOA rs701567 and GRIN2B rs1019385 interact such
that the risk of hospital admission is higher with a greater
number of non-ancestral alleles. 
This is the first time that allele frequencies in the candidate
genes studies here have been described for the mixed
ancestry population of South Africa. SNP frequencies were
broadly similar to reported frequencies for Caucasian groups
described elsewhere (NCBI http://www.ncbi.nlm.nih.gov).22 No
difference in frequency was detected for the ancestral allele
for GRM3 rs6465084 and of GRIN2B rs1019385 in individuals
of both Caucasian and mixed ancestry. The A/G alleles of
DAOA rs701567 were found to occur at almost equal
Figure 1: A three dimensional bar chart illustrating the
modelled interaction of DAOA rs701567 and GRIN2B
rs1019385 on the logarithm of the number of
hospitalisations for mania.
Table I: SNP Allele Frequencies For Each of the Candidate Genes
Gene SNP Ethnic Group No. of Cases No. of Controls Ancestral Allele Ancestral Allele p-value
Frequency Cases Frequency Controls
GRM3 rs6465084 Caucasian, Mixed Ancestry 132 188 0.75 0.77 0.5953
Caucasian only 69 89 0.73 0.78 0.3054
Mixed Ancestry only 63 99 0.77 0.76 0.7887
GRIN2B rs1019385 Caucasian, Mixed Ancestry 132 188 0.35 0.34 0.8268
Caucasian only 69 89 0.41 0.40 0.9181
Mixed Ancestry only 63 99 0.29 0.28 0.8304
DAOA rs701567 Caucasian, Mixed Ancestry 132 188 0.43 0.48 0.2000
Caucasian only 69 89 0.41 0.41 0.8961
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frequencies in both population groups. 
We did not demonstrate that any of the putative risk alleles
were associated with BD diagnosis. This is consistent with the
lack of consistently reproducible associations between individual
genes and BD diagnosis even in large data sets.33 There is
increasing evidence that BD is a disorder where many genes of
small effect contribute to risk of developing the disorder.20
In this study, we observed that the G allele at SNP
rs6465084 GRM3 carries a 4 times greater risk of developing
psychosis in subjects with BD. This is unexpected as the A
allele in this SNP has been weakly associated with SZ
diagnosis– and might be expected to be a risk factor for
psychosis in BD.20 This finding by Egan et al., however, was not
replicated by others.34,35 Egan et al. also reported an
association between the A allele, impaired list learning and
verbal fluency, and low prefrontal levels of glutamate
transporter EEAT2 in normal subjects and people with SZ.20 It
is possible to speculate that the A allele confers a risk of a
dysexecutive syndrome typical of certain types of SZ, while the
G allele is associated with normal or enhanced executive
function, consistent with the finding by Diller et al. that GRM3 is
a gene which has evolved favourable new (derived) alleles.36
The G allele may, however, together with other risk factors, be
associated with more severe mania. Crespi et al. identified
GRM3 as a gene with significant evidence of selection in
human populations, and although not enough is known about
this SNP in global populations or its function in normal or
disease states, it may be one which differentiates Kraepelinean
“dementia praecox” from “manic depression”.19,37
The rs701567 SNP in DAOA was not associated with BD
diagnosis in this study, contrary to the finding of Fallin et al.16
The G allele was not associated with any phenotype or severity
measures; however there was a significant gene-gene
interaction with GRIN2B rs1019385 SNP on the number of
hospitalisations for mania. In the South African context,
hospitalisation is most often required for emergency treatment
of severe episodes. The combination of both ancestral alleles
(G for DAOA and T for GRIN2B) conferred the lowest risk of
admission while homozygotes with a derived allele/ancestral
allele combination had the highest risk for hospitalisation.
Homozygotes for both derived alleles had a relatively low risk
of hospitalisation. DAOA activates DAO which determines
synaptic glutamate and serine levels, while NMDA receptor
function varies according to glutamate levels and GRIN2B
genotype. Both DAOA and GRIN2B form part of the
phosphoinositide-3 kinase/ AKT-signalling network (PI3K/AKT),
involved in the regulation of cell proliferation, growth,
development and apoptosis.38,39 We may speculate that
heterozygotes have intermediate glutamate function and
homozygotes an inflexible regulatory capacity for glutamate
load or deficiency states, compromising normal neural
development and plasticity.
A major limitation of this study was the relatively small
sample size. To avoid this, recent studies have focussed on
obtaining large consortia for genetic association tests. An
example of this would be the Wellcome Trust Case Control
Consortium which investigated the genetic basis of seven
common diseases, including BD, using 2000 affected
individuals for each disorder and 3000 shared controls. The
outcome of this study was that modest genetic effects were
able to be detected using larger sample sizes.40
The most constraining limitation of the current study is the
lack of information about the in vivo and in vitro function of the
specific SNPs examined. Future work is needed to determine the
functionality of glutamate SNPs in terms of gene expression and
physiological correlates, and whether these link to phenotypes
for BD. The interaction between DAOA rs701567 and GRIN2B
rs1019385 may be indirect or direct and if direct could be
examined with a protein interaction assay such as yeast-2-hybrid
screen. Other SNPs in the genes we examined and other genes
involved in glutamate metabolism including glutamate receptor,
ionotropic, N-methyl D-aspartate 1 (GRIN1), glutamate receptor,
metabotropic 1 (GRM1) and glutamate receptor, ionotropic,
kainate 1 (GRIK1) and their interactions with BD phenotypes
should also be explored. Another consideration for future work
would be to have greater detail regarding cognitive phenotype.
This could be helpful to test (post-hoc) hypotheses related to
cognitive function in, for example, controls with GRM3 rs6465084
derived allele homozygotes.
Conclusion
To our knowledge this is the first study investigating these 3
glutamatergic SNPs and their interactions with BD diagnosis
and phenotype. The study provided preliminary evidence that
ancestral alleles in the 3 SNPs examined have a protective
effect by decreasing the chances of having more severe
phenotypes of BD, specifically psychosis and repeat hospital
admission. It is possible to speculate that newly derived genes
associated with various evolutionary advantages (including
perhaps cognitive advantages), may also increase the risk for
more severe bipolar disorder. However, findings from this pilot
study warrant further research and validation. 
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